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 Human immunodeficiency virus type 1 (HIV-1) infection entails the sequential 
interaction of the viral Env complex with the cellular CD4 receptor and a chemokine coreceptor, 
culminating in the fusion of the viral and cellular membranes. Sequestration of membrane 
cholesterol and the inhibition of glycosphingolipid synthesis have suggested a role of liquid 
ordered (lo) raft microdomains in HIV-1 entry into target cells.
 We devised two different strategies to inhibit HIV-1 infection by targeting lipid rafts 
in the host cell. First, we targeted a fusion inhibitor (T20) to the membrane of target cells, 
specifically inside or outside lipid rafts. Notably, we found that the T20 peptide has a tendency 
to insert itself in cellular membranes. Here we demonstrate that membrane-anchored T20 is 
able to inhibit Env-mediated cell-cell fusion, although low concentrations of the fusion inhibitor 
anchored to the membrane of target cells are not sufficient to prevent infection by free HIV-1 
viruses. Given that HIV-1 has been reported to exit the cell through lipid rafts and incorporate 
raft-associated cellular proteins in its envelope during exit, we also analysed the infectivity 
of HIV-1 pseudotypes produced in T20-expressing cells. We found that ADA-T20 viruses are 
more infectious than viruses produced in control cells, which suggests that the propensity of 
the peptide to insert in the outer membrane leaflet of membranes may favour the anchoring of 
the virus to the target cell.
 The second strategy involves the inhibition of dihydroceramide desaturase, the 
enzyme responsible for converting dihydroceramide to ceramide, with the ceramide analogue 
GT11. We show here that dihydroceramide desaturase inhibition results in the accumulation 
of saturated dihydrosphingomyelin in detergent-resistant membranes of GT11-treated cells. 
Although GT11 alters the lipid composition of lo domains, it does not significantly affect the 
localization of raft-associated proteins, nor does it alter chemotaxis and antigen-induced 
activation of T cells. Nonetheless, we found that GT11 is able to prevent both Env-mediated 
cell-cell fusion and infection by free HIV-1 pseudotyped viruses in a dose-dependent manner. 
The replacement of sphingomyelin for dihydrosphingomyelin in lipid rafts of GT11-treated 
cells increases the rigidity of lo domains, and these biophysical changes may explain the drug’s 
antiviral activity. However, ADA viruses produced in GT11-treated cells are more infectious 
than those produced in untreated cells, which suggests that the antiretroviral effect of drugs 
that modulate membrane fluidity is complex and requires further investigation.
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Figure 1. Structure of a HIV-1 viral particle.
Schematic representation of a mature HIV-1 virion.
1. The Human Immunodeficiency Virus Type I
 1.1  AIDS - an emerging epidemic
 The Acquired Immunodeficiency Syndrome, commonly referred to as AIDS, is a disease 
that affects more than 30 million people worldwide, according to the latest estimates from the 
World Health Organization (see www.unaids.org for recent data about the epidemic). The 
causative agent is the Human Immunodeficiency Virus (HIV), a retrovirus of the Lentivirinae 
subfamily first identified in 1983 by Luc Montagnier at the Institute Pasteur in France (Barre-
Sinoussi et al., 183; Hoffman, 200; Levy et al., 184). The virus primarily infects cells from 
the immune system that possess a CD4 receptor, such as T-lymphocytes and macrophages 
(Dalgleish et al., 184; Landau et al., 188; Maddon et al., 186), and for that reason HIV induces 
a slow but steady decrease in the number of these cells in the organism. Indeed, individuals 
that are infected with HIV can live for several years without any discernible symptom, and 
only after the number of T-lymphocytes drops below a given threshold (normally below 200 
cells per mm3 of blood) does the person enter the so-called AIDS phase of the disease, with the 
appearance of opportunistic infections (tuberculosis, Kaposi’s sarcoma, hepatitis, pneumonia) 
and a prognosis of death within 2-3 years (Hoffman, 200; Kahn and Walker, 18; Wei et al., 
15). Since the first cases of AIDS were reported in the early 1980’s, the disease has been 
studied and better understood, with treatment plans developed over the years. Consequently, 
the life expectancy for an HIV-infected individual has increased greatly and AIDS has, to some 
degree, become a manageable disease. However, a cure has not been found yet and new strains 
of viruses resistant to the existing therapy are surfacing everyday.
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 1.2  Structure of the virus particle
 HIV belongs to the Lentivirinae subfamily of retroviruses, having been identified so far 
two different species, HIV type 1 and HIV type 2. These show very different pathogenecity 
and, while HIV-2 is largely confined to West Africa, HIV-1 is highly disseminated globally 
and accounts for the vast majority of AIDS cases worldwide (Reeves and Doms, 2002). HIV-1 
is characterized by a RNA genome in the form of two single-stranded molecules, which are 
composed by three main regions, gag-pol-env, flanked by long terminal repeat (LTR) regions 
necessary for the intermediate step in retrotranscribing the RNA genome into a DNA molecule 
(Sierra et al., 2005; Turner and Summers, 1). Furthermore, the viral particle is around 100-
120 nm in diameter and possesses a lipid envelope derived from the host cell membrane, 
surrounding a cone-shaped capsid composed of p24 proteins (Figure 1). Between the envelope 
and the capsid, subunits of the viral p17 protein comprise the matrix of the virion, confering 
it integrity, and inside the capsid we can find not only the nucleocapsid (p9 and p6 proteins 
closely attached to the RNA dimer) but also viral enzymes necessary for the replication cycle: 
the reverse transcriptase, the integrase and the protease. Embedded in the viral envelope are 
the so-called viral spikes (also called Env complexes), trimers of two non-covalently attached 
glycoproteins, gp120 and gp41. These play an important role in the entry of the virus in the cell 
(Sierra et al., 2005; Turner and Summers, 1).
 1.3  Replication cycle overview
 The first step in the infection cycle of HIV-1 is the attachment of gp120 to the CD4 
receptor at the surface of the target cell (Landau et al., 188) (Figure 2). The virus is able to 
infect cells from the immune system that express the CD4 receptor, mainly T-lymphocytes and 
macrophages, although it has also been described to infect dendritic cells and CD4 negative 
cells, such as microglial cells of the central nervous system (Cosenza et al., 2002; Dalgleish et 
al., 184; Engering et al., 2002; Maddon et al., 186). Furthermore, in order to enter the cell 
HIV-1 also needs to attach itself to a second receptor, which was found to be a member of the 
seven transmembrane domain G protein-coupled receptors, or GPCRs (Deng et al., 16; Feng 
et al., 16). These receptors respond to chemokines, small peptides that function as potent 
chemoattractants for leukocyte subpopulations. HIV-1 hijacks either the CCR5 or the CXCR4 
chemokine receptors for entering the target cell, although other chemokine receptors have also 
been described as coreceptors or as being required for entry (Deng et al., 1; Rucker et al., 
1). According to the tropism of the virus for either coreceptor, HIV-1 has been classically 
categorized as follows: M-tropic strain, that uses the CCR5 receptor to infect macrophages, 
is mainly responsible for the initial stages in HIV-1 infection and is not associated with the 
formation of syncytia (fusion between Env-expressing cells and CD4+ cells, leading to the 
formation of giant multinucleated cells); T-tropic strain, that uses the CXCR4 receptor to 
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Figure 2. HIV-1 life cycle.
Schematic representation of the life cycle of HIV-1. (1) Attachment of the virus to cell receptors. (2) 
Fusion of the viral and cellular membranes, and release of the viral capsid inside the cell. (3) Retrotran-
scription of the single strand RNA into a double strand DNA. (4) Transport of the viral DNA into the 
nucleus and integration in the cell’s genome. (5) Viral transcription and replication. (6) Assembly of 
viral particles. () Budding of viral particles from the cell. (8) Maturation of the virion.
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infect T-lymphocytes, arises in the later stages of AIDS infection and is reported to induce 
the formation of syncytia; and last, dual-tropic strain, that can use either coreceptor to infect 
both macrophages and T-lymphocytes (Berger et al., 18; Deng et al., 16; Feng et al., 16; 
Tersmette et al., 188). After interacting with the chemokine coreceptor, the Env complex adopts 
a fusogenic conformation that permits the fusion of both the viral envelope and the membrane 
of the target cell, with the release of the viral capsid in the cytoplasm (Chan and Kim, 18; 
Markosyan et al., 2003). This process will be discussed later.
 The next step in HIV-1 replication cycle is the uncoating of the viral capsid with the 
subsequent retrotranscription of the RNA genome into a double-stranded DNA, a process 
mediated by the viral reverse transcriptase (Figure 2).  At this stage, the viral protein Vif is 
essential to counteract the antiviral effects of the cellular protein APOBEC3G, a cytidine 
deaminase responsible for the introduction of C to U mutations in the negative strand of the 
DNA molecule. Vif downregulates APOBEC3G and prevents it from being integrated in nascent 
virions (Kozak et al., 2006; Sheehy et al., 2002). Once the viral genome is in the form of a DNA 
molecule, it enters the nucleus of the cell and the integrase mediates the insertion of the viral 
DNA into the cell’s own genome. The virus can lie in a dormant state if the cell is not activated, 
since the first round of viral replication, that produces the regulatory proteins Tat, Rev and 
Nef, is mediated by cellular transcription factors such as NF-κβ (Hiscott et al., 2001; Nabel and 
Baltimore, 18). When sufficient amounts of Tat are produced, it activates transcription of 
more Tat, Rev and Nef proteins through binding to the LTR region in the integrated viral 
DNA and other cellular transcription activators, inducing the production of multi-spliced 
mRNAs that remain retained in the nucleus of the cell (Feinberg et al., 11; Ruben et al., 18). 
Once the levels of Rev increase, this protein is able to bind unspliced or single-spliced mRNAs 
and transport them to the cytoplasm to the cell, where they will be translated in several viral 
proteins important for the assembly and release of new virions (Malim et al., 18).
 The mRNAs transported to the cytoplasm of the cell give rise to the precursor proteins 
gp160, Gag and Gag-Pol (Figure 2). Gp160, a result of the translation of the env gene, is glycosilated 
in the endoplasmic reticulum and proteolitically cleaved in two different glycoproteins, gp120 
and gp41, in the Golgi apparatus. The glycoproteins anchor themselves in the membrane of the 
cell, in the final form of a homotrimer of heterodimers, with three subunits of each glycoprotein 
present in each Env complex (Earl et al., 11). On the other hand, the Gag polyprotein is a 
55 KDa protein that possesses the matrix, nucleocapsid and the capsid viral proteins (among 
others), and travels to the membrane of the cell where it becomes anchored (Burniston et al., 
1; Gottlinger et al., 18; Sandefur et al., 2000). The Gag-Pol polyprotein, which results from a 
-1 frameshift in the transcription of the Gag precursor ( Jacks et al., 188), additionally contains 
the enzymes reverse transcriptase, integrase and protease, which will be incorporated in the 
newly-formed viral particles. The Gag and Gag-Pol precursors form multimers that travel and 
attach themselves to the inner leaflet of the cell membrane, also transporting genomic copies 
of HIV in the form of RNA molecules. The multimerization induces the outwards formation 
of roughly spherical structures that contain the RNA molecules and the Gag and Gag-Pol 
precursors inside, and eventually these structures give rise to immature virus particles that 
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leave the cell through a budding process, maintaining the cell membrane as its viral envelope 
with the Env complexes already anchored and several other cellular proteins (Gottlinger et 
al., 18; Jouvenet et al., 2006; Nguyen and Hildreth, 2000). Once outside the cell, the virion 
undergoes maturation through the autoexcision of the protease from the Gag-Pol polyproteins 
and the subsequent processing of the remaining proteins in the viral precursors. The newly-
formed viral particles are now fully infectious and ready to initiate a new replication cycle 
(Bukrinskaya, 2004; Ganser-Pornillos et al., 2008). 
 1.4  Current treatment options
 Since the discovery of the causative agent of AIDS until the present day, many resources 
have been employed in the development of potentials drugs that are able to inhibit some 
step in the replication cycle of the virus, although a complete cure has not been achieved 
yet. Several classes of antiretroviral drugs are already available for treatment regimens, such 
as nucleoside/nucleotide or non-nucleoside inhibitors of the reverse transcriptase, inhibitors 
of the viral protease and inhibitors of the integrase (De Clercq, 2002). Since the virus has a 
high rate of mutation, due to the lack of proof-reading when retrotranscribing its genome, the 
emergence of resistant strains to the existing treatment is very high. While some of the acquired 
mutations are detrimental to the virus, others are beneficial in surpassing the obstacles created 
by the antiretroviral drugs (Martinez-Picado et al., 2000). This problem has been partially 
overcome by the combination of three or more inhibitors from at least two different classes of 
antiretroviral drugs, in what is called HAART, or Highly Active AntiRetroviral Therapy. This 
treatment plan has improved enormously the life expectancy of HIV-1-infected patients, by 
attacking the virus in more than one stage in its replication cycle, but there is a great need for 
further investigation of new targets of inhibition to combat newly acquired resistance by the 
virus (Hughes et al., 2008).
 Recently, a new class of antiretroviral drugs became available in HAART treatment, 
usually used as a salvage therapy for patients that have developed multi-drug resistant strains 
of the virus. This new class targets the entry process (Starr-Spires and Collman, 2002), either 
by inhibiting the fusion of membranes mediated by gp41 (Enfuvirtide, which was approved 
for clinical use in 2003) (Matthews et al., 2004) or, in more recent times, by preventing the 
attachment of the virus to the CCR5 chemokine coreceptor (Maraviroc, which began clinical 
use in 2007) (Lieberman-Blum et al., 2008). Still under investigation are maturation inhibitors, 
drugs that prevent the processing of the Gag polyprotein and thus the production of mature 
capsid proteins, resulting in non-infectious viral particles (Salzwedel et al., 200).
 Another approach taken by the scientific community is the development of an HIV-1 
vaccine, mostly as a preventive measure in populations in high risk of infection (Walker and 
Burton, 2008). However, this approach has proved fruitless over the past few years, as the 
main candidates AIDSVAX and V520 have shown no significant reduction in the incidence of 
HIV-1 infection in the participants of the clinical trials where the vaccines were administered 
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(indeed, some controversial data indicate that V520 may have even increased the risk of HIV-1 
infection) (Francis et al., 18; James, 2003; Priddy et al., 2008; Timberg, 200). The reasons for 
the failure in the development of an effective HIV-1 vaccine are mainly due to the glycosilation 
of gp120, which masks the already highly mutable epitopes found in this glycoprotein (Huang 
et al., 2008). 
2. Mechanism of HIV-1 entry into target cells
 2.1  Attachment to the CD4 receptor
 The entry of HIV-1 in T-cells is a complex, multi-step process that involves several cell 
factors and viral proteins. The first event to take place is the engagement by the virus of the CD4 
receptor at the surface of the target cell (Dalgleish et al., 184; Landau et al., 188) (Figure 3). CD4 
is a 55-60 KDa member of the immunoglobulin superfamily, that possesses four extracellular 
domains (D1, D2, D3 and D4), a hydrophobic transmembrane domain and a cytoplasmic tail 
(Maddon et al., 185). The D1 domain is important to interact with major histocompatibility 
complex (MHC) class II molecules in antigen-presenting cells, and consequently CD4 acts as 
a costimulatory receptor in the formation of the T cell receptor (TCR) complex (Bowers et al., 
1; Rudolph et al., 2006). Furthermore, the intracellular cytoplasmic tail interacts with the 
tyrosine kinase Lck and induces a signalling cascade resulting in the activation of the cell 
(Bowers et al., 1; Turner et al., 10). In the case of HIV-1, the interaction between CD4 and 
the virus is mediated by the gp120 glycoprotein, present in each Env complex in the form of 
a trimer, non-covalently attached to three other gp41 subunits (Roux and Taylor, 200). Gp120 
possesses five conserved domains, buried inside the molecule, separated by five hypervariable 
regions; even though part of the molecule is exposed to the host’s immune system, its high 
glycosilation and mutation rates allow the virus to escape neutralization by antibodies elicited 
against it (DeVico, 200; Huang et al., 2008). After attaching itself to the D1 domain of the CD4 
receptor, the gp120 subunits undergo conformational changes that allow them to interact with 
the second receptor necessary for cell entry, either CXCR4 or CCR5, depending on the viral 
strain (Kwong et al., 18; Wu et al., 16). 
 It should be mentioned that HIV-1, in certain instances, is able to infect cells that 
don’t express the CD4 receptor, such as epithelial cells of the mucosal surfaces (through the 
glycosphingolipid galactosyl-ceramide, GalCer) (Yahi et al., 12), cells from the nervous 
system (using the mannose receptor) (Liu et al., 2004), and dendritic cells (mostly through 
the C-type lectin DC-SIGN) (Geijtenbeek and van Kooyk, 2003; Turville et al., 2002). In the 
latter, the receptor DC-SIGN recognizes the high mannose content of gp120 and mediates the 
internalization, though not the infection, of HIV-1 in the cell. The dendritic cell then travels to 
the lymph nodes, matures, and transfers the still infectious virus to CD4+ T-cells, where it can 
initiate a productive infection (Engering et al., 2002; Wu and KewalRamani, 2006). 
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Figure 3. HIV-1 entry in the target cell.
Detailed scheme of the entry of an HIV-1 viral particle in the target cell. (1) Attachment of the gp120 
glycoprotein to the CD4 receptor. (2) Gp120 conformational change and attachment to the chemok-
ine coreceptor. Formation of a multimeric gp120-CD4-coreceptor complex. (3) Insertion of gp41 fusion 
peptides in the cell membrane. (4) Formation of a six-helix bundle and fusion of the viral and cellular 
membranes.
 2.2  Attachment to a chemokine co-receptor
 The second cell receptors to be engaged by the virus in the entry process are members 
of the seven transmembrane family of G protein-coupled receptors (Figure 3), responsible for 
the detection of chemotactic gradients and the ability of the cells to migrate towards them 
(Murdoch and Finn, 2000; Murphy, 14). These receptors are characterized by a short N-terminal 
extracellular region, seven helical transmembrane domains with three extracellular and three 
intracellular loops, and a C-terminal cytoplasmic tail; the second intracellular loop has been 
reported to interact with G proteins upon receptor activation by the corresponding chemokine 
(Gilman, 18; Moro et al., 13). The chemokine receptors most used by the virus are CXCR4 
(Feng et al., 16), whose ligand is SDF-α (CXCL12), and CCR5 (Deng et al., 16), which binds 
RANTES (CCL5), MIP-1α (CCL3), MIP-1β (CCL4) and CCL8. Indeed, these chemokines have 
been shown to be able to inhibit HIV-1 entry in the cell, by acting as viral competitors for the 
corresponding receptors (Bleul et al., 16; Cocchi et al., 15). However, there are reports of 
the virus using other GPCRs as co-receptors for entry, such as CCR3, CCR2b and CCR8 (Choe 
et al., 16; Doranz et al., 16; Rucker et al., 1); nonetheless, these infections are rare and 
less efficient than the ones mediated by CCR5 and CXCR4. 
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The gp41 glycoprotein is composed by a N-terminal fusion peptide, two heptad repeat regions sepa-
rated by a hinge region with two cysteine residues, an hydrophobic transmembrane region, and a C-
terminal cytoplasmic tail. FP, fusion peptide. TM, transmembrane region. CC, cysteine residues.
 The conformation that gp120 adopts upon attachment to the CD4 receptor presumably 
exposes crucial regions necessary for the binding of the glycoprotein with either CXCR4 and/
or CCR5 (Thali et al., 13) (Figure 3). Studies have demonstrated the importance of the N-
terminal region and the extracellular loops of the receptors in this interaction (Liu et al., 2003), 
and the relevance of the V3 variable region of gp120 in determining the tropism of the virus for 
either receptor (Cocchi et al., 16; Hwang et al., 11). This second receptor binding induces the 
dissociation of the gp120 trimer from the Env complex (Moore et al., 10), and the consequent 
exposure of the gp41 subunits that leads to a third fusion-active conformation of the viral spike 
(Figure 3).
 2.3  Fusion of the membranes
 Following shedding of the gp120 subunits from the Env complex, the virus initiates the 
stage of membrane fusion mediated by the gp41 glycoproteins (Figure 3). Gp41 possesses an 
N-terminal ectodomain, a hydrophobic transmembrane region, and a C-terminal cytoplasmic 
tail; furthermore, the ectodomain consists of an aminoterminal nonpolar fusion peptide (FP) 
rich in glycines, two leucine zipper-like 4-3 regions consistent with the formation of α-helices 
(N-terminal heptad repeat 1, HR1, and C-terminal heptad repeat 2, HR2), and a hinge region 
between the heptad repeat regions that contains two important cysteine residues (Dong et al., 
2001; Lu et al., 15; Weissenhorn et al., 1) (Figure 4). The next step in the entry process 
is the formation of a coiled-coil with the HR1 regions of the gp41 subunits, which thrusts 
the aminoterminal fusion peptides to insert themselves in the membrane of the target cell 
(Markosyan et al., 2003; Weissenhorn et al., 1) (Figure 3). This causes the opening of a labile 
fusion pore in the cell membrane, one that can be closed if the fusion process is halted by low 
temperatures or inhibitory peptides (Markosyan et al., 2003). The gp41 molecules now adopt 
a fusogenic conformation and fold themselves, bringing together both the viral and the cell 
membranes and simultaneously allowing for the interaction between the HR1 and the HR2 
regions. These contain complementary sequences that associate in an antiparallel manner in a 
structure called six-helix bundle (6HB), a cluster of six α-helices formed by the three HR1 and 
the three HR2 regions in each Env complex. The fusion pore becomes stable and the fusion 
of the membranes occurs, with the release of the viral capsid inside the cell (Chan et al., 1; 
Markosyan et al., 2003) (Figure 3). 
INTRODUCTION
-3-
 The entry process of the virus in the cell requires several factors in order to be successful. 
Studies have demonstrated that the density of the receptors for HIV-1 entry is essential for the 
establishment of a productive infection; multiple Env trimers are required to engage several CD4 
and co-receptor molecules to activate the kinetics necessary for the fusion of the membranes 
(Kuhmann et al., 2000; Layne et al., 10). Moreover, the conformation that the receptors adopt 
in the membrane and their affinity for gp120 are also relevant for HIV-1 binding and entry in 
the cell (Doms, 2000).
 2.4  The fusion inhibitor enfuvirtide
 At the stage where the fusion peptides of the gp41 subunits are already inserted in the 
membrane of the target cell, but the six-helix bundle has not yet formed, there is a pre-fusion 
conformation of gp41 (so-called pre-hairpin intermediate) which can last for several minutes 
before advancing into the full fusion-competent conformation (Markosyan et al., 2003). In this 
step, the HR1 regions are exposed and various C-peptides (derived from the HR2 region) 
have already been demonstrated to have the capacity to recognize the hydrophobic grooves 
on the surface of the coiled coil and inhibit the formation of the six-helix bundle, preventing 
altogether the fusion of the membranes (Chan and Kim, 18; Wild et al., 12; Wild et al., 14) 
(Figure 5). 
 One such peptide, corresponding to the HR2 region of gp41 (residues 643-678 of HIVLAI 
gp160), is enfuvirtide, previously named DP-178 and T20 (Kilby et al., 18) (Figure 5). Early 
in vitro studies have demonstrated the efficacy of enfuvirtide in inhibiting HIV-1-induced 
syncitium formation with an IC90 of 1,5 ng/mL (Wild et al., 14). Interestingly, the aminoacid 
residues complementary to enfuvirtide are only adjacent to the hydrophobic groove in HR1 
to which other C-peptides strongly adhere (Chan et al., 18); nonetheless, it shows more 
inhibitory efficacy than these (Kliger et al., 2001). Besides the accepted mode of action for 
these peptides (Kliger and Shai, 2000), some authors believe that enfuvirtide might also be 
able to bind the fusion peptide based on circular dichroism studies (Liu et al., 2005). Another 
interesting finding is the propensity that enfuvirtide shows to insert itself in the outer leaflet of 
liposomes, which might bear relevance to its inhibitory action in vivo (Kliger et al., 2001; Veiga 
et al., 2004); the membrane of the target cell, upon treatment with the drug, might act as an 
enfuvirtide reservoir and readily present the peptide when the virus approaches the cell.
Enfuvirtide has undergone several phase I/II/III clinical trials, in which its ability to 
significantly reduce viral loads in infected patients and partly restore CD4+ cell counts has 
been documented (Kilby et al., 18; Lalezari et al., 2003a; Matthews et al., 2004). Moreover, two 
large-scale phase III clinical trials provided evidence that this compound is active against viral 
strains resistant to several other antiretroviral drugs (Lalezari et al., 2003b; Lazzarin et al., 2003; 
Matthews et al., 2004). Adverse effects associated with enfuvirtide treatment were reported, 
but for the most part were local injection site reactions and not considered severe enough to 
discontinue treatment (Lalezari et al., 2003b; Lazzarin et al., 2003). The results derived from 
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Figure 5. T20 mechanism of fusion inhibition.
(1) Gp41 aminoacid residues that correspond to the T20 peptide. (2) Mechanism of fusion inhibition 
by the T20 peptide. The T20 peptides recognize and attach to the complementary residues in the HR1 
region and prevent the formation of the six-helix bundle. 
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the clinical trials have prompted the approval of the drug for commercial use in March 2003, 
and since then it has been successfully used as a salvage therapy for treatment-experienced 
patients. 
 The clinical trials and these recent years of enfuvirtide implementation on HAART 
have demonstrated that continued exposure to the drug leads to the emergence of resistant 
viral strains, similar to what happens with other classes of antiretrovirals (Matthews et al., 2004; 
Wei et al., 2002). Mapping studies indicated that the most common mutations that the virus 
undergoes to acquire resistance to enfuvirtide are aminoacid substitutions in residues 36-45, 
particularly in the GIV motif (residues 36-38) (Rimsky et al., 18). In fact, due not only to the 
appearance of resistant strains but also to other issues associated with enfuvirtide treatment 
(lack of oral availability, high costs of manufacture, local injection site reactions) (Matthews et 
al., 2004), an Austrian-based group has demonstrated in vitro that a membrane-bound version 
of the peptide in target cells is able to inhibit HIV-1 entry, with the intention of using this 
strategy in future gene therapy approaches (Egelhofer et al., 2004).
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3. Lipid rafts in the cell membrane
 3.1  Structure and lipid composition
 The fluid mosaic model proposed by S. J. Singer and Garth L. Nicolson to illustrate the 
arrangement of lipids and proteins in the membrane of the cell was first described in 1972, 
and remained the classical view of cell membrane structure until recently (Singer and Nicolson, 
12). In this model, the main components of the cell membrane are arranged in a random 
manner, with phospholipids forming a lipid bilayer and proteins, either integral or peripheral, 
distributed homogenously and capable of lateral diffusion without restrainment. Numerous 
studies have refined this view of cell membrane organization, mainly through the observation 
that non-ionic detergents, such as Triton X-100, are not able to completely solubilize the cell 
membrane at low temperatures. From these experiments came the notion of low-density 
detergent-resistant membranes (DRMs), or detergent-insoluble glycolipid-enriched complexes 
(DIGs), fractions of the cell membrane high in sphingolipids and cholesterol that partition 
from the rest of the phospholipid-rich membrane (Ahmed et al., 1; London and Brown, 2000; 
Schroeder et al., 18). 
Studies have shown that the coexistence of (glycerol)phospholipids and sphingolipids 
in membranes induces the separation of these components into different phases, due to their 
structure (Figure 6). Phospholipids typically have kinked unsaturated acyl chains, with multiple 
double bonds and a low Tm, which results in a liquid-disordered (ld) state of the membrane, 
while sphingolipids, with their saturated or mono-unsaturated acyl chains and high Tm, 
induce the formation of a highly ordered solid-like gel phase, completely segregated from 
the fluid state conferred by the phospholipids. However, cholesterol interacts preferentially 
with sphingolipids and alters the gel conformation of pure sphingolipid-domains to a liquid-
ordered (lo) phase, lowering the Tm and allowing for lateral mobility in the membrane (Bunge et 
al., 2008; Estep et al., 1; Filippov et al., 2004; Frazier et al., 200). These lo domains found in the 
membrane of the cells, which account for the majority of isolated DRMs, are named lipid rafts 
and show an asymmetric nature, with sphingolipids, sphingomyelin and cholesterol enriched 
in the outer leaflet while cholesterol and phospholipids with saturated hydrocarbon chains 
(such as phosphatidylinositol and phosphatildylethanolamine) are predominant in the inner 
leaflet (Brown and London, 2000; Fridriksson et al., 1; Simons and Ikonen, 1).
A closer look at sphingolipid structure reveals that they consist of long chain bases 
(most commonly sphingosine) linked by an amide bond to a fatty acid, and to complex 
carbohydrate or polar head groups via their terminal hydroxyl group.  Sphingomyelin 
and phosphatidylcholine, for instance, both possess phosphorylcholine as the polar head 
group (Ramstedt and Slotte, 2002), while gangliosides have instead a carbohydrate moiety 
containing sialic acids. The sphingosine unit modified by the long chain fatty acid is referred 
to as ceramide, a key intermediate in the synthesis of complex sphingolipids (Brown, 18; 
Fantini et al., 2002). Ceramide is formed by the introduction of a trans 4,5 double-bond in 
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Figure 6. Lipid and protein composition of the cell membrane.
dihydroceramide, the direct saturated precursor of ceramide, by the enzyme dihydroceramide 
desaturase (DHCDase) (Figure ). It will then give rise to various gangliosides in the membrane, 
sphingomyelin, and other sphingolipids of importance to the cell (Lahiri and Futerman, 200; 
Rawat et al., 2005). Furthermore, the catabolism of sphingomyelin, mediated by the action 
of acid sphingomyelinase or phospholipase C, is also able to generate de novo ceramide; this 
effect is stimulated by numerous factors including apoptosis-inducing agents (irradiation, 
heat shock, toxins), which is in accordance with the well-documented implication of ceramide 
in the regulation of programmed cell death (Cifone et al., 14; Santana et al., 16; Zhang et al., 
2001).
 3.2  Protein composition
 Several proteins are known to partition preferentially in lipid rafts, essentially taking 
advantage of its particular lipid composition. The glycosylphosphatidylinositol (GPI) anchor, 
that attaches peripheral proteins to the outer leaflet of the membrane, and both the myristate 
and palmitate acyl chains, that direct proteins to the inner leaflet of the membrane, are common 
raft-targeting signals used by the cell (Brown and Rose, 12; Resh, 1). Notable examples of 
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Figure . Ceramide biosynthesis.
Ceramide is formed from serine and palmitoyl-coA, and gives rise to sphingomyelin and gangliosides, 
among others.
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proteins that use these signals to partition to lipid rafts are the CD14, CD24, CD55 and CD59 
receptors with GPI anchors, and members of the Src family of tyrosine protein kinases, as well 
as the Gα subunits of heterotrimeric G proteins, that use the aforementioned palmitoylation 
signals (Moffett et al., 2000; Resh, 14; Stefanova et al., 11).  On the other hand, prenylation 
seems to work as a raft-disfavouring signal, since its branched structure does not pack well in 
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Figure 8. Clustering of lipid rafts at the cell membrane.
the liquid-ordered arrangement of lipid rafts (Melkonian et al., 1); indeed, it has been shown 
that, as mentioned above, the acylated Gα subunit of heterotrimeric G proteins associates better 
with lipid rafts than the full heterotrimeric Gαiβγ complex with its prenylated Gβγ subunits 
(Moffett et al., 2000). 
 Transmembrane proteins are less common in lipid rafts, mainly because the 
hydrophobic membrane-spanning domains do not fit well in its lipid structure (Lucero and 
Robbins, 2004). However, linkage of two or more palmitoyl chains to the cytoplasmic domain of 
transmembrane proteins has been shown to act as a raft-targeting signal in some proteins, such 
as the tetraspanin CD81 and the T-cell receptors CD4 and CD8 (Arcaro et al., 2000; Cherukuri 
et al., 2004; Fragoso et al., 2003). In fact, the function of the majority of lipid raft-associated 
transmembrane proteins is dependent on the palmitoylation signals they possess, implying a 
more direct role of these domains in the functionality of the cell other than a mere scaffold to 
which proteins attach. 
 3.3  Function in the context of the cell
 Lipid rafts have the capacity to move laterally in the membrane, serving as dynamic 
platforms that coalesce with each other to form larger domains and facilitate interactions 
between previously separated proteins (Harder and Simons, 1; Simons and Ikonen, 1) 
(Figure 8). This property, commonly referred to as lipid raft clustering, is able to increase the 
stability and the initial size of individual rafts from 50-70 nm (or even less) to more than 500 
nm for clustered domains (Gupta and DeFranco, 2003), as studies using single particle tracking 
and fluorescence resonance energy transfer (FRET) have shown (Kenworthy et al., 2000; Kusumi 
et al., 2004; Murase et al., 2004; Prior et al., 2003; Sharma et al., 2004). Several mechanisms 
have been implicated in lipid raft clustering, such as ligand binding to receptors, antibody 
crosslinking, or even cytoskeleton-induced interaction of proteins found in rafts (Harder et al., 
18; Rodgers and Zavzavadjian, 2001; Simons and Toomre, 2000). Furthermore, it has also been 
found that the aforementioned mechanisms have the ability to increase the raft affinity of a 
protein initially not associated with these domains, which in turn activates a cascade of events 
that enhances raft clustering (Field et al., 15; Prieschl and Baumruker, 2000). 
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 The transient or constitutive association of specific proteins with lipid rafts, and their 
capacity to coalesce in large platforms, are the basis of lipid raft implication in cell function 
(Brown and London, 2000; Simons and Ikonen, 1). Rafts are important for such processes as 
cell proliferation, apoptosis, migration as well as infection by several pathogens, such as HIV-1 
(Fantini et al., 2002; Grassme et al., 2001; Inokuchi et al., 2000; Manes et al., 2003; Manes et al., 1). 
For instance, both p56Lck and LAT (Linker of Activated T cells) are crucial proteins involved 
in T-cell receptor-mediated signalling and their activity is dependent on their attachment to 
lipid rafts (Brdicka et al., 18; Zhang et al., 18a). Studies have shown that a mutant non-
palmitoylated form of Lck that does not associate with lipid rafts is not able to interact with its 
signalling partners in the TCR complex and become phosphorylated, although the mutation 
does not render the protein inactive per se. Similarly, the transmembrane LAT protein cannot 
function in T-cell signalling if its palmitoylation site is absent and the protein is excluded from 
lipid rafts (Lin et al., 1; Zhang et al., 18b). Other examples describe how sphingolipid 
depletion in lipid rafts affects the localization of Src kinases and the overall proliferation 
capacity of mouse lung carcinoma cells (Inokuchi et al., 2000), and how raft disruption by 
sequestering cholesterol can impair the ability of a human breast cancer cells to migrate in 
response to a chemoattractant gradient (Liu et al., 200). 
 Although the actin cytoskeleton is not directly associated with lipid rafts, its role in 
several cell functions depends on rafts, such as lymphocyte migration and activation (Manes 
and Viola, 2006; Viola and Gupta, 200). By rearranging actin filaments, the cell is able to induce 
lateral movement of raft-associated transmembrane proteins anchored to them and create 
supramolecular clusters necessary for a given cell function. For instance, in TCR signalling, 
ligand binding induces the formation of an immunological synapse at the contact region between 
the T-cell and the antigen-presenting cell (APC); this immunological synapse is composed of a 
variety of T-cell receptors and signalling molecules (Lck, ZAP70, LAT, SLP76), which undergo 
a complex relocation due to the reorganization of the actin cytoskeleton (Chichili and Rodgers, 
200; Meiri, 2004; Valensin et al., 2002). 
 Another object of interest for these microdomains is their implication in disease; 
several pathogens, from viruses to bacterial toxins, are reported to use lipid rafts as sites of 
entry and even exit from the target cell (Chazal and Gerlier, 2003; Simons and Ehehalt, 2002; van 
der Goot and Harder, 2001). More specifically, it has been postulated that lipid rafts provide 
high amounts of low-affinity receptors to which the pathogens attach, further stabilize them 
and in some cases induce a conformational change in the pathogen’s structure, necessary 
for a subsequent interaction with a high-affinity receptor less abundant in the membrane 
(Montecucco, 186). Notable examples are the binding of cholera toxin to the raft-based 
ganglioside GM1 (Badizadegan et al., 2000), the interaction of Shiga toxin to the Gb3 glycolipid 
found in lipid rafts (Lingwood, 1), and the attachment of tetanus and botulinum toxins to 
several di- and tri-sialogangliosides present in lipid rafts of neural cells (Kitamura et al., 1; 
Simpson and Rapport, 11; van Heyningen, 14). In the case of the Shiga toxin, not only do lipid 
rafts act as binding sites to the target cell, but they also transport the toxin inside the cell into 
the endoplasmic reticulum, through clathrin-dependent endocytosis (Falguieres et al., 2001). 
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Additionally, lipid rafts have also been implicated in the budding of influenza virus from the 
target cell (also in HIV-1, as will be discussed ahead), in efficient prion conversion that takes 
place in Creutzfeldt-Jakob disease, and in the formation of amyloid plaques in Alzheimer 
disease (Fantini et al., 2002; Kakio et al., 2001; Nayak et al., 2004; Sanghera and Pinheiro, 2002; 
Zhang et al., 2000).
 3.4  Role of lipid rafts in HIV-1 infection
 It has been suggested that HIV-1 takes advantage of the existence of lipid rafts, and their 
importance in the cell, in various stages during its replication cycle. Not only the entry and exit 
of the virus from the cell take place in lipid rafts, but also viral regulatory proteins specifically 
interact with these domains with the intention of affecting cell signalling and promoting the 
production of infective virions (Campbell et al., 2001).
 Shortly after infecting a new host, HIV-1 needs to penetrate a barrier of mucosal 
epithelial cells in the gastrointestinal, anorectal or genitourinary tracts. Since these cells do 
not express the receptors necessary for HIV-1 entry in the cell, the virus has taken advantage 
of a common mechanism of macromolecule transport in epithelial cells, transcytosis, to pass 
from the apical to the basolateral side of these cells without actually infecting them (Bomsel, 
1). Lipid rafts are important in this respect because the virus binds to raft-based GalCer to 
gain entry into the cell, and disrupting this association prevents viral transcytosis (Alfsen et al., 
2001; Yahi et al., 12). Also the productive infection of immune cells, through binding of the 
virus to the CD4 receptor and a chemokine coreceptor (either CXCR4 or CCR5), is a process in 
which lipid rafts play an essential role. Studies have shown that these receptors are localized 
in raft microdomains, and that the clustering ability of lipid rafts is crucial for the entry of the 
virus in the cell (Manes et al., 2000; Nguyen et al., 2005; Popik et al., 2002). Targeting CD4 to 
non-raft portions of the membrane does not impair the attachment of gp120 to this receptor, 
but the trimeric gp120-CD4-coreceptor complex, necessary for posterior fusion events, does 
not form (Del Real et al., 2002). The reason lies in the fact that binding of gp120 to raft-based 
CD4 triggers lateral diffusion and coalescence of individual rafts, bringing together gp120-
CD4 complexes with rafts that possess either CXCR4 or CCR5, and if CD4 is localized outside 
rafts clustering does not occur (Del Real et al., 2002) (although opposite results have also been 
reported (Percherancier et al., 2003; Popik and Alce, 2004)). Furthermore, some studies refer 
that the gp120 glycoprotein also shows binding affinity to sphingolipids found in lipid rafts, 
particularly the ganglioside GM3 and the globotriaosylceramide Gb3, which might assist in 
HIV-1 entry into the cell (Hug et al., 2000; Puri et al., 2004); this data helps consolidates the 
notion that lipid rafts are fundamental for a productive infection to take place.
 Once inside the cell, the virus continues to use lipid rafts to its benefit. Several viral 
proteins are reported to bind to these domains and alter cell signalling to accommodate 
vital changes necessary for the production of infective viral particles. One notable example 
is Nef, a peripheral, myristoylated membrane protein that interacts with raft-associated 
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nonreceptor tyrosine kinases of the Src family. It induces T-cell activation in the absence of 
stimulation, by clustering via lipid rafts such signalling molecules as Lck, Fyn and Hck, and 
subsequently promotes viral replication (Wang et al., 2000). It has also been described its effect 
in downregulating CD4 expression in the cell, allowing for efficient incorporation of Env in 
the viral particle (Lama et al., 1) and avoiding superinfection of infected cells (Wildum et 
al., 2006). Furthermore, Nef inhibits apoptosis of the infected cell, by reducing intracellular 
p53 concentration and activation (Greenway et al., 2002), and decreases the expression of MHC 
class I molecules on the cell surface, effectively rendering the infected cell undetectable to 
CD8+ cytotoxic T-cells (Schwartz et al., 16).
 Other viral proteins that possess either myristoylation and/or palmitoylation signals 
that target them to lipid rafts are the Env glycoprotein complex and the Gag and Gag-Pol 
precursors. Env is synthesized as a 160 KDa precursor (as was mentioned before), that 
posteriorly undergoes cleavage and palmitoylation in the Golgi apparatus (Earl et al., 11; 
Rousso et al., 2000). There is evidence that indicates that lipid rafts are also assembled in Golgi 
and subsequently travel to the cell membrane where they become incorporated (Smart et al., 
1); through the palmitoylation signals, it is possible that the Env complex interacts with 
these lipid raft precursor structures still in the Golgi apparatus and later is incorporated in 
the membrane of the infected cell, where the budding of new virions will occur (Nguyen and 
Hildreth, 2000). Also the Gag and Gag-Pol precursors are myristoylated in the p17 matrix 
subunits, which directs them to the internal leaflet of lipid rafts (Ono and Freed, 1), and the 
oligomerization that these precursors undergo in the assembly of new virions helps cluster 
more raft units with gp120-gp41 complexes embedded (Lindwasser and Resh, 2001). 
 Finally, as would be expected, the budding of viral particles from the cell takes place 
in lipid rafts (Nguyen and Hildreth, 2000). Analyses of HIV-1 envelope lipid composition of 
infectious virions have shown a high content in cholesterol and sphingolipids, as opposed 
to phospholipids (Aloia et al., 13). Additionally, treatment of viruses with β-cyclodextrin, 
a cholesterol-chelating agent, results in non-infectious viral particles, demonstrating the 
importance of lipid raft structure and composition to the virus (Campbell et al., 2002). In 
accordance with these data, a number of cellular proteins associated with lipid rafts have been 
detected in viral particles, such as CD55, CD59 and MHC class II molecules; the virus benefits 
from this fortuitous coincidence by interfering with virus-specific humoral responses and 
possibly stabilizing its attachment with the target cell, through CD4-MHC class II interactions 
(Arthur et al., 12; Cantin et al., 1; Esser et al., 2001; Lamarre et al., 18; Montefiori et al., 
14).
 3.5  Artefact or real?
 Since the concept of lipid rafts was first introduced in the scientific community, 
researchers have been divided in the question of whether these microdomains really exist 
in the cell membrane or are merely an artefactual result derived from detergent extraction 
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at low temperatures (Edidin, 2001; Munro, 2003). In fact, the definition of detergent-resistant 
membranes comes from a biochemical operation, and given that phase-separation is strongly 
dependent on temperature (Bunge et al., 2008), new methods and techniques to isolate and/or 
visualise lipid rafts were in need to prove their existence in physiological conditions.
 Still on the subject of membrane solubility with a non-ionic detergent, one major 
problem with Triton X-100 is the need for chilling before extraction, which presumably alters 
lipid distribution in the membrane and can lead to artificial raft formation and clustering 
(Heerklotz, 2002). The discovery of Brij 98 as an alternative detergent that can be used at 37ºC, 
has brought new insight into this technique. Rafts isolated with Brij 98 still possess much of 
the same proteins detected in Triton X-100 rafts, and interestingly, their size was around 70 
nm, which probably corresponds to individual rafts (Drevot et al., 2002). Yet another detergent, 
Lubrol WX, is also used in cold extraction, although the lipid domains isolated with this 
detergent possess a different composition than the ones isolated with Triton X-100 (Delaunay 
et al., 2008; Lucero and Robbins, 2004; Roper et al., 2000); far from disconcerting, this evidence 
points towards the existence of distinct types of raft units involved in separated cell functions, 
that behave differently when subjected to extraction with different detergents (Schuck et al., 
2003). 
 The visualization of rafts in cells has always been an appealing yet complicated 
challenge to overcome. The small size of these microdomains makes it difficult to detect them 
by microscopy, and therefore the most usual method applied is the clustering of several raft 
units by antibodies against known raft-associated markers (proteins or lipids) (Harder et al., 
18). A common example, although in this case not involving a protein localized in lipid 
rafts, is the usage of the B subunit of cholera toxin (CTx) as a binding agent and cross-linker 
of the ganglioside GM1 found in lipid rafts; this technique is extensively used in fluorescence 
microscopy (some examples in (Manes et al., 2000; Popik et al., 2002)). Additionally, FRET and 
single-particle tracking experiments have provided evidence that a GPI-anchored protein is 
organized in clusters and transiently confined to domains sensitive to a glycosphingolipid 
synthesis inhibitor, consistent with lipid rafts (Kenworthy and Edidin, 18; Kenworthy et al., 
2000; Sharma et al., 2004; Sheets et al., 1). Furthermore, another group has constructed 
proteins with different transmembrane domains, to direct them either to raft or non-raft 
portions of the membrane, and using single-molecule tracking has concluded that the diffusion 
of raft-associated proteins is significantly reduced when compared to their non-raft protein 
counterparts, and additionally that cholesterol depletion minimizes those differences (Pralle et 
al., 2000). Although some researchers argue that sequestering cholesterol is a drastic move that 
may affect not only the composition of the membrane but also the correct functioning of the cell 
(Edidin, 2001; Pike and Miller, 18), the use of glycosphingolipid synthesis inhibitors provides 
the same indication that these experiments interfere with lipid rafts in the membrane, as was 
mentioned above (Sheets et al., 1). Overall, and given the assigned important roles that 
lipid rafts have in the context of the cell, growing evidence is surfacing everyday to support 
the existence of these microdomains in the membrane. 
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1. Target T20 chimeric peptides to the external leaflet of cell membranes and 
analyse their effect in HIV-1 infection.
1.1 Generate stable cell lines that express raft-associated or raft-excluded 
membrane-anchored T20.
1.2 Analyse the effect of membrane-bound T20 in Env-mediated cell-cell 
fusion.
1.3 Analyse the effect of membrane-bound T20 in infection by free HIV-1 
pseudotypes.
1.4 Determine the infectivity of HIV-1 pseudotypes produced in T20-expressing 
cells.
2. Inhibit the enzyme dihydroceramide desaturase (DHCDase) and analyse its 
effect in HIV-infection.
2.1 Determine the cellular toxicity of the DHCDase inhibitor GT11, and its 
derivative GT11pyr.
2.2 Analyse the effect of GT11 in Env-mediated cell-cell fusion.
 2.3 Analyse the effect of GT11 in infection by free HIV-1 pseudotypes.
2.4 Study the effect of GT11 in T cell-associated functions. 
2.5 Analyse the lipid composition of lipid rafts in GT11-treated cells.
2.6 Study the localization of raft-associated proteins in GT11-treated cells.
2. Study the biophysical properties of dihydrosphingomyelin-containing 
membranes.
2.8 Determine the infectivity of HIV-1 pseudotypes produced in GT11-treated 
cells.
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General procedures
Cell lines used and cultivation methods
The adherent cell lines HEK-293T, HEK-293, HEK-293CD4 (that contains a stably 
transfected plasmid that encodes for the CD4 receptor) and TZM-b1 (a HeLa-derived cell line 
that expresses high levels of CD4, CCR5 and CXCR4) were cultured in DMEM medium (Lonza 
BioWhittaker) with 10% FCS, 2mM L-glutamine, sodium pyruvate and antibiotics (complete 
medium), unless explained otherwise. HEK-293CD4 cells were also cultured in the presence of 
G418 (1 mg/mL), to select for cells that express the CD4 receptor. The Jurkat suspension cell 
line was maintained in RPMI medium (Lonza BioWhittaker) with 10% FCS, 2 mM glutamine, 
sodium pyruvate, antibiotics and non-essential aminoacids (complete medium), unless 
mentioned otherwise                               .
Peripheral blood mononuclear cells (PBMCs) were obtained from healthy donors 
through centrifugation at 2000 g for 30 min in a Ficoll-Paque gradient (Pharmacia). After 
centrifugation a thin layer of PBMCs (buffy coat) is recovered and washed twice to remove 
platelet contamination. The PBMCs were then stimulated in vitro with phytohemaglutinin-L 
(PHA-L; 1 µg/mL; Difco) for 24h at 37ºC, in complete RPMI medium plus human interleukin 
2 (IL-2; 20 ng/mL; Hoffman-LaRoche). PHA-L was removed from the medium and the cells 
were maintained in culture with the remaining components, unless detailed otherwise. 
Effect of membrane-bound T20 in HIV-1 infection
T20LDL and T20GPI cloning procedures
To generate a construct that encodes a membrane-bound version of T20 localized outside 
lipid rafts, the extracellular (a short sequence), transmembrane and juxtamembrane low-
density lipoprotein receptor (LDLR) sequences, the cytoplasmic region of CD46, a small signal 
peptide that directs the chimera to the membrane and the T20 peptide were cloned together. 
The T20 sequence present in a previously available T20GPI-containing vector (gift from Patrick 
Keller) was first amplified using the primers P/T20-KPNI/FW and P/T20-HINDIII/RV, and 
cloned in frame in the pLGFP-GT46 vector (P. Keller, Max Planck Institute of Cell biology and 
Genetics, Dresden, Germany), yielding T20-LDL-CD46. After several intermediate steps, this 
construct was then introduced in a bicistronic pRV-IRES-GFP vector (Genetrix, Madrid, Spain), 
along with a short signal peptide sequence, to yield SP-T20-LDL-CD46 (further referred to as 
T20LDL). The primer sequences are shown in Table I.
To generate a construct with the T20 peptide, the sequence encoding for a 
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glycosylphosphatidylinositol (GPI) anchor and a short signal peptide, the SP-T20-GPI sequence 
from the aforementioned T20GPI-containing vector was cloned in pRV-IRES GFP, to yield SP-
T20-GPI (T20GPI in future references).
Table I. Primers used to clone T20LDL.
P/T20-XMNI/FW 5’ TATGGTACCCATGTACACAAGCTT 3’
P/T20-HINDIII/RV 5’ TACAAGCTTGAACCAATTCCACAG 3’
Generation of T20-expressing stable cell lines
HEK-293T cells were transfected by either calcium phosphate method or JetPEI (Poly 
Transfection) with pVSVG, a vector that codifies for the VSVG envelope (Genetrix, Madrid, 
Spain), pGag-Pol, that possesses the rest of the viral proteins necessary for the formation of 
retroviral particles (Genetrix, Madrid, Spain), and either one of the retroviral constructs pRV-
IRES-GFP+T20LDL or pRV-IRES-GFP+T20GPI. 48h after transfection the viral supernatants 
were recollected, filtered, concentrated (ultracentrifugation at 50000 g for 2h, 4ºC, in a Beckman 
Coulter centrifuge), and infected in either HEK-293T cells or HEK-293CD4 cells. The resulting 
cell lines were sorted in a Coulter Epics Altra cytometer (Beckman Coulter) for GFP expression 
and, whenever necessary, for T20 expression using the 2F5 antibody (2 ug/mL; provided by 
Dr. Hermann Katinger through the NIH AIDS Research References Reagents Program) and a 
secondary anti-human IgG-PE antibody (Beckman Coulter).
Immunostaining for T20 presence in the membrane
T20LDL and T20GPI stable cell lines were stained for expression of T20 in the membrane 
with the 2F5 antibody (2 ug/mL) for 1h at 4ºC, followed by incubation (also 1h, 4ºC) with a 
secondary anti-human IgG-PE antibody (Beckman Coulter). The cells were further analised by 
flow cytometry.
For measuring the propensity of T20 to insert itself in the lipid bilayer of cells, HEK-
293CD4 cells were incubated with either 0, 0.1, 0.5, 1, 2 or 6 µg of T20 peptide (provided by the 
Proteomics Service of the Centro Nacional de Biotecnologia, Madrid, Spain) per 2 × 105 cells 
for 24h at 37ºC. The cells were then stained with 2F5 antibody for 30 min at 4ºC and analised 
by flow cytometry.
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Detection of T20 in lipid rafts using DRM isolation
T20LDL- and T20GPI-expressing HEK-293CD4 stable cell lines were lysed at 4ºC for 20 
min in TNEX buffer (50 mM Tris-HCL pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.5% Triton X-100) 
plus protease and phosphatase inhibitors (aproteinin, leupeptin, PMSF, NaVO4, NaF). The cell 
lysates were mixed with an Optiprep solution (Nycomed Pharma, Oslo, Norway) at 60% to yield 
a 35% final concentration. After adding a 30% Optiprep solution to the 35% lysate-Optiprep 
mix in SW-41 centrifuge tubes (Beckman Instruments, Inc., Palo Alto, CA), detergent-resistant 
membranes (DRMs) were isolated by ultracentrifugation (170000 g, Beckman Coulter) for 4h at 
4ºC. Six fractions were recovered from the ultracentrifugation, the first two ones corresponding 
to DRMs, and the last ones containing the remaining cellular proteins. Normalized protein 
amounts determined for each fraction were resolved in a SDS-PAGE gel and transferred to 
nitrocellulose membrane (Pharmacia) for western-blot analysis. Blotting was performed with 
the 2F5 antibody (2 ug/mL), for T20 detection, anti-transferrin receptor (0,25 µg/mL; Zymed 
Laboratories) and anti-caveolin-1 (0,4 µg/mL; Santa Cruz Biotechnologies, Inc.), as negative 
and positive controls for raft-associated proteins, respectively. 
Immunofluorescence (copatching) experiments for visualization of T20 in 
the membrane 
T20LDL and T20GPI stable cell lines (HEK-293T) were placed in fibronectin-coated 
chambers (10 ug/mL), allowed to adhere for 4h at 37ºC, and incubated with the 2F5 antibody 
(2 ug/mL) for 30 min at 12ºC. After washing twice with DMEM + 0.2% BSA (at 4ºC), the cells 
were incubated with anti-human IgG-Cy5 antibody (Jackson ImmunoResearch, Inc.) for 30 
min at 12ºC, and halfway into the incubation cholera toxin subunit β-biotin antibody (6 µg/
mL; Sigma Aldrich), against GM1, was added to the cells. Another washing step preceded the 
final incubation with streptavidin-Cy3 antibody (Jackson ImmunoResearch, Inc.), 30 min at 
12ºC. The cells were fixed with 3,7% paraformaldehyde (5 min at 4ºC) and cold methanol (5 
min at 4ºC), mounted in Vectashield medium (Vector Laboratories) and analysed by confocal 
microscopy (Olympus). The images were processed using Image J software.
Env-mediated cell-cell fusion assays using T20-expressing cell lines 
T20LDL- and T20GPI-expressing HEK-293CD4 stable cell lines, HEK-293 and HEK-
293CD4 cells were transfected (using JetPEI) with a pSCluc plasmid containing the firefly 
luciferase gene under the control of the vaccinia virus 7.5 promoter (provided by D. Rodriguez, 
Centro Nacional de Biotecnología, Madrid, Spain), and pNull promoterless renilla luciferase 
plasmid (gift from Gustavo del Real). A vaccinia virus that codifies for HIV-1envIIIB was infected 
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in HEK-293 effector cells for 1h at 37ºC, and the cells were further maintained in culture for 12h 
in the presence of 100 µg/mL rifampicin (Boehringer Mannhem). 36h after transfection, the 
infected HEK-293 cells were co-cultured with the transfected cells (in 1:2 ratio) in the presence 
of rifampicin, for 6h at 37ºC. To the transfected HEK-293CD4 cells was also added either 0, 
0.5, 1, 2 or 6 µg/mL of T20 peptide 24h before co-culturing with the infected cells, and the 
peptide was maintained throughout the 6h-long incubation. Moreover, the CXCR4-antagonist 
AMD3100 (10 µM; Sigma Aldrich) was added to the transfected HEK-293CD4 cells for 5 min at 
37ºC previous to the co-culture with the infected cells, as a positive control for fusion inhibition. 
Cell-cell fusion was analysed by luciferase activity measurement in cell lysates (Passive Lysis 
Buffer, from Promega), by use of a Dual Luciferase Reporter Assay System (Promega). Relative 
Light Units (RLUs) were calculated as the quotient between firefly and renilla activity values, 
and were indicative of the occurrence of fusion between the transfected and the infected 
cells. 
Production of replication-deficient HIV-1 pseudotypes and infection in 
T20-expressing cells
To generate replication-deficient HIV-1 viruses pseudotyped with different envelopes, 
HEK-293T cells were transfected (JetPEI or Calcium Phosphate Transfection kit, Invitrogen) 
with the pNL4.3lucR-E- vector (gift from Rafael Delgado, Hospital 12 de Octubre, Madrid, 
Spain), an HIV-1 expression vector modified with the luciferase gene (inserted in the nef gene) 
and deficient in env and vpr, and an expression vector that codifies for a given viral envelope: 
pADAenv (an R5 HIV-1 envelope), pNL4.3env (an X4 HIV-1 envelope) or pVSVGenv (from the 
vesicular stomatitis virus). All vectors were provided by Rafael Delgado. 48h after transfection 
the viral supernatants were recollected, centrifuged to remove cell contamination, and stored 
in aliquots at -80ºC. An ELISA for p24 detection (Innogenetics) was performed in order to 
quantify the viral supernatants.
To perform an infection assay, TZM-b1 cells were transfected with either pRV + T20LDL 
or pRV + T20GPI for expression of T20 at the membrane, and that expression was monitored 
by flow cytometry using the 2F5 antibody (2 µg/mL). The cells were then plated in p24 wells 
for infection, and 36h after transfection with the T20-expressing vectors, viral supernatants 
corresponding to 30 ng of p24 antigen, in the case of ADA and NL4.3, or 8 ng in the case 
of VSVG, were added to the cells for 24h at 37ºC. The medium was replaced and 48h later 
the cells were lysed (Passive Lysis Buffer) and infection was assessed by luciferase activity 
measurement. TZM-b1 cells were also incubated 24h before infection with 0, 2, 5 or 10 µg/mL 
of T20 peptide, which was renewed when the infection was initiated.      
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Production of replication-deficient HIV-1 pseudotypes in T20-expressing 
cells and infection in TZM-B1 cells
To generate replication-deficient HIV-1 viruses that express T20 in their envelopes, 
T20LDL and T20GPI stable cell lines (HEK-293T) were transfected with the pNL4.3lucR-
E- vector and either pADAenv, pADAenv 38E/42S (with a two-aminoacid substitution that 
confers resistance to T20-mediated inhibition), pADAenv 38A/42T (another two-aminoacid 
substitution that confers resistance to T20-mediated inhibition), pNL4.3env, pNL4.3env 
38E/42S (the same two-aminoacid substitution as in pADAenv 38E/42S) and pVSVGenv. All 
vectors were a kind gift from Rafael Delgado. In addition, HEK-293T were also transfected to 
produce control viral supernatants for posterior infection assays. 48h after transfection the viral 
supernatants were recollected, centrifuged to remove cell contamination and stored in aliquots 
at -80ºC. An ELISA for p24 detection (Innogenetics) was performed in order to quantify the 
viral supernatants.
To perform an infection with the viral supernatants derived from T20-expressing cells, 
TZM-b1 cells were plated in p24 wells 24h before infection. The cells were also incubated with 
0, 2, 5 or 10 µg/mL of T20 peptide, which was renewed when the infection was initiated. Viral 
supernatants corresponding to 25-30 ng of p24 antigen, or 8 ng in the case of pVSVGenv, were 
added to the cells for 24h at 37ºC. The medium was replaced and 48h later the cells were lysed 
(Passive Lysis Buffer) and infection was assessed by luciferase activity measurement.
Effect of the inhibition of dihydroceramide desaturase (DHCDase) in 
HIV-1 infection
Viability and cell cycle analyses
Activated human PBMCs were incubated with 0, 0.1, 0.5, 1 or 2 µM of GT11 C8 (gift 
from Gemma Fabriàs, IIQAB, Barcelona, Spain) for 3 consecutive days, with GT11 C8 being 
replaced once daily. The cells were, on the one hand, counted every day using a Trypan Blue 
dye exclusion method to stain for dead cells, and on the other hand fixed with 70% ethanol 
at -20ºC for cell cycle analysis. The fixed cells were then stained with DNA Prep (Beckman 
Coulter) and analysed by flow cytometry.
Jurkat cells and activated human PBMCs were incubated for 3 consecutive days with 
0, 1, 2, 5, 10, and 15 µM of GT11pyr (gift from Gemma Fabriàs), in the case of Jurkat cells, or 0, 
0.5, 1, 2, 5 and 10 µM of GT11pyr, in the case of PBMCs (GT11pyr was replaced twice daily). 
As with GT11 C8, all the cells were counted every day and stained for cell cycle analysis. 
Additionally, HEK-293 cells were also incubated with 0, 15, 30 or 60 µM of GT11pyr, and the 
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cells were counted every day using Trypan Blue. 
Citotoxicity assays
TZM-b1 cells were plated in p96 wells and incubated for 24h with 0, 1, 2, 4, 8, 16, 32 or 
64 µM of GT11pyr. Cell toxicity was assessed by adding MTS (Promega) to the p96 wells for 
2-4h before measuring absorbance at 492 nm. LD50 was determined as the concentration that 
corresponds to half the absorbance level of control wells. 
Migration assays using modified Boyden chambers
In vitro migration assays were performed using modified Boyden chambers 
(Costar, Cambridge, MA), in which a chemotactic gradient is formed between two separate 
compartments communicated by a porous membrane. Chambers with a pore size of 5 µm 
were used for Jurkat cells, and with a pore size of 3 µm for activated human PBMCs. 
In the case of Jurkat cells, cells were incubated with either 0.2 or 2 µM of GT11 C8 in 
basal medium for 24h. The cells were then placed in the open chamber of each well while the 
lower part received either complete medium, basal medium, or basal medium + 10 nM human 
SDF-1α (Prepotech, Inc.). GT11 C8 was renewed in both the upper chambers and in the wells. 
After 3-4h at 37ºC, the cells that had passed through the pore membrane into the lower part of 
the well were recovered and counted by flow cytometry. Additionally, Jurkat cells were also 
incubated with 0, 1, 2, 5 or 10 µM of GT11pyr for 8h in complete medium and overnight in 
basal medium (RPMI + 0,1% BSA), with renewal of GT11pyr once. The rest of the procedure 
continued as described above.
In the case of PBMCs, cells were incubated with 0, 0.5, 1, 2 or 5 µM of GT11pyr in 
complete medium + IL-2 for 24h before depleting the cells in basal medium for 3h, renewing 
GT11pyr once during the 24h-incubation and again in the depletion period. The rest of the 
procedure continued as described above. 
Analysis of PBMCs activation through quantification of IFNγ 
production
Non-stimulated human PBMCs (right after Ficoll-Paque separation, before stimulating 
with PHA-L and IL-2) were incubated with 0, 0.5, 1, 2, 5, or 10 µM of GT11pyr, in complete 
RPMI medium without FCS, for 36h at 37ºC. GT11pyr was replaced twice during the incubation 
period. The cells were then plated in p96 wells coated with anti-CD3 antibody (5 µg/mL; 
eBioscience) and anti-CD28 antibody (5 µg/mL; Pharmingen), in order to activate them, and 
incubated for 12h at 37ºC (in the presence of GT11pyr). The supernatant of the wells was 
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recollected and quantified for IFNγ using an human IFNγ ELISA kit from R&D Systems.
DRM isolation for determination of lipid composition and CD4 
localization
HEK-293CD4 cells were incubated for 24h at 37ºC with 0, 15, 30 or 60 µM of GT11pyr, 
which was renewed once during the incubation period. Afterwards, cells were lysed and DRM 
fraccionation was performed as detailed above (see “Detection of T20 in lipid rafts using DRM 
isolation”). Of the six fractions recovered from the ultracentrifugation, half was processed for 
lipid composition analysis, using High Performance Liquid Chromatography (HPLC) coupled 
to time of fly (TOF) mass spectrometry (HPLC-MS), and the remaining half was analysed for 
CD4 localization by western-blot. Blotting was performed with anti-CD4 antibody (1 µg/mL; 
Santa Cruz Biotechnology, Inc.), anti-transferrin receptor (0,25 µg/mL; Zymed Laboratories) 
and anti-caveolin-1 (0,4 µg/mL; Santa Cruz Biotechnology, Inc.), the last ones serving as 
negative and positive controls for raft-associated proteins, respectively. 
Immunofluorescence (copatching) experiments for visualization of raft-
associated proteins
HEK-293CD4 cells were transfected (JetPEI) with a vector encoding for a GFPGPI 
construct (P. Keller, Max Planck Institute of Cell biology and Genetics, Dresden, Germany), 
and the following day the cells were incubated with either 0 or 60 µM of GT11pyr, for an 
additional 24h (GT11pyr was renewed once). The cells were then placed in fibronectin-coated 
chambers and allowed to adhere for 4h at 37ºC, in the presence of GT11pyr. Afterwards, the 
untransfected HEK-293CD4 cells were incubated for 30 min at 12ºC with either anti-CD4 
antibody (on one occasion HP2.6, 20 µg/mL, and on another occasion anti-CD4 coupled to 
FITC, [], from Immunotech) or anti-CXCR4 antibody (K1046; Santa Cruz Biotechnology, Inc.), 
and 10 minutes before the end of the incubation to all cells (including to the GFP-GPI transfected 
ones) was added cholera toxin subunit β-biotin antibody (6 µg/mL; Sigma Aldrich). The cells 
were then washed twice with DMEM + 0,2% BSA (at 4ºC), and incubated for an additional 20 
min at 12ºC with anti-mouse IgG-Cy2 antibody (Jackson ImmunoResearch, Inc.) in the case of 
the CD4 wells, anti-rabbit IgG-Alexa Fluor 488 antibody (Molecular Probes) in the case of the 
CXCR4 wells, and streptavidin-Cy3 antibody (Jackson ImmunoResearch, Inc.) for all wells. The 
cells were fixed with 3,7% paraformaldehyde (5 min at 4ºC) and cold methanol (5 min at 4ºC), 
mounted in Vectashield medium with DAPI (Vector Laboratories) and analysed by confocal 
microscopy (Olympus). The images were processed using Image J software. (Olympus). 
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Env-mediated cell-cell fusion assays using GT11-treated cells 
HEK-293 and HEK-293CD4 cells were transfected (using JetPEI) with a pSCluc plasmid 
containing the firefly luciferase gene under the control of the vaccinia virus 7.5 promoter, and 
pNull promoterless renilla luciferase plasmid. 24h after transfection, the transfected HEK-
293CD4 cells were also incubated with 0, 0.01, 0.1, 0.5, 1, 5 or 10 µM of GT11 C8 for an additional 
24h. A vaccinia virus that codifies for HIV-1envIIIB was infected in HEK-293 effector cells for 1h 
at 37ºC, and the cells were further maintained in culture for 12h in the presence of 100 µg/mL 
rifampicin (Boehringer Mannhem). Afterwards, the infected HEK-293 cells were co-cultured 
with the transfected cells (in 1:2 ratio) in the presence of rifampicin, for 6h at 37ºC. Cell-cell 
fusion was analysed by luciferase activity measurement in cell lysates (Passive Lysis Buffer, 
from Promega), by use of a Dual Luciferase Reporter Assay System (Promega). Relative Light 
Units (RLUs) were calculated as the quotient between firefly and renilla activity values, and 
were indicative of the occurrence of fusion between the transfected and the infected cells. 
Production of replication-deficient HIV-1 pseudotypes and infection in 
GT11pyr-incubated cells
To generate replication-deficient HIV-1 viruses pseudotyped with different envelopes, 
HEK-293T cells were transfected with the pNL4.3lucR-E- vector and either pADAenv, 
pNL4.3env or pVSVGenv. 48h after transfection the viral supernatants were recollected, 
centrifuged to remove cell contamination, and stored in aliquots at -80ºC. An ELISA for p24 
detection (Innogenetics) was performed in order to quantify the viral supernatants.
To perform an infection in cells incubated with high doses of GT11pyr, TZM-b1 cells 
were incubated with either 0, 15, 20 or 30 µM of GT11pyr for 24h, during which GT11pyr was 
renewed once. Viral supernatants corresponding to 45 ng of p24 antigen were added to the 
cells for 24h at 37ºC (GT11pyr incubation was maintained but not renewed). The medium was 
replaced and 48h/72h later the cells were lysed (Passive Lysis Buffer). Infection was assessed 
by luciferase activity measurement. 
To perform a “chronic treatment” of TZM-b1 cells with low concentrations of GT11pyr, 
the cells were incubated with either 0, 0.5, 1, 1.5 or 2 µM of GT11pyr in complete medium 
with 5% FCS for 36h, 60h or 84h before infection (GT11pyr was replaced twice daily). Viral 
supernatants corresponding to 25 ng of p24 antigen were added to the cells for 24h at 37ºC 
(GT11pyr incubation was maintained but not renewed). The medium was replaced and 48h 
later the cells were lysed (Passive Lysis Buffer). Infection was assessed by luciferase activity 
measurement.
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Production of replication-deficient HIV-1 pseudotypes in GT11pyr-
incubated cells and infection of TZM-B1 cells
To generate replication-deficient HIV-1 viruses pseudotyped with different envelopes, 
HEK-293T were transfected with the pNL4.3lucR-E- vector and pADAenv. 12h after transfection 
the cells were incubated with either 0 or 30 µM of GT11pyr, which was maintained for a 
further 36h (GT11pyr was renewed once). Afterwards, the viral supernatants were recollected, 
centrifuged to remove cell contamination, concentrated (ultracentrifugation at 52000 g for 
2h, 15ºC, in a Beckman Coulter centrifuge) and stored in aliquots at -80ºC. An ELISA for p24 
detection (Innogenetics) was performed in order to quantify the viral supernatants.
To perform an infection with the viral supernatants derived from GT11pyr-incubated 
cells, TZM-b1 cells were plated in p24 wells 24h before infection. Viral supernatants 
corresponding to 35 ng of p24 antigen were added to the cells for 24h at 37ºC. The medium 
was replaced and 48h later the cells were lysed (Passive Lysis Buffer). Infection was assessed 
by luciferase activity measurement. 
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Figure . Soluble T20 peptide is able to insert itself in 
the membrane of cells.
HEK-293CD4 cells were incubated with 0, 0.1, 0.5 or 
1 μg of T20 peptide for 24h at 37ºC. Staining for T20 
in the membrane was performed using 2F5 mAb, and 
the cells were analysed by flow cytometry. 
1. Effect of membrane-bound T20 in HIV-1 infection
  The discovery of the T20 peptide as a novel inhibitor in HIV-1 infection was a scientific 
breakthrough in HIV-1 research. This peptide has been shown to inhibit HIV-1-induced 
syncitium formation at low concentrations (IC90 of 1,5 ng/mL, (Wild et al., 14)), presumably 
by interacting with the HR1 region in the gp41 glycoprotein complementary to its aminoacid 
residues and effectively preventing the formation of the six-helix bundle (Chan and Kim, 18; 
Wild et al., 12; Wild et al., 14). 
1.1 Analysis of the insertion of gp41-derived T20 peptide in the membrane of 
target cells
Previous studies have suggested the propensity of T20 to insert itself in the outer 
leaflet of liposomes, which might be important to its inhibitory action in vivo. Indeed, it has 
been suggested that the membrane of the target cell might act as a reservoir of T20 molecules 
that are present at the site of entry of HIV-1 in the cell, in an unspecific manner (Veiga et al., 
2004). To gain further insight on the ability of soluble T20 to insert in the membrane of target 
cells, a synthetic version of the T20 peptide was added to HEK-293CD4 cells for 24h. After 
washing, cells were stained with the 2F5 antibody, a specific antibody that recognizes a gp41 
epitope present in T20 (provided by Dr. Hermann Katinger through the NIH AIDS Research 
and References Reagents Program). Flow cytometry analysis confirmed that T20 was bound 
in the membrane of the cells, as is shown in Figure . Furthermore, a dose-dependent increase 
of the soluble peptide was observed; cell incubation with increasing concentrations of the 
T20 peptide shifted fluorescent curves to the right. These results suggest that the T20 peptide 
inserts in the membrane of target cells.
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Figure 10. Aminoacid sequence of T20LDL and T20GPI constructs.
MELFWSIVFTVLLSFSCRGSDWES   LQSTVP   MYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF   YDPRPSSGHSRYALIPIPLAVITTCIVLYMNVL
MELFWSIVFTVLLSFSCRGSDWES   DPQEF   MYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF   KLNGSKLQRP
HQALGDVAGRGNEKKPSSVR   ALSIVLPIVLLVFLCLGVFLLW   KNWRLKN    LYKS   TYLTDETHREVKFTTSL
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1.2 Generation and expression of membrane-anchored versions of T20 
peptide
 The results described above prompted us to direct T20 to the membrane of HIV-1 target 
cells, specifically inside or outside lipid rafts. In 2001, Hildinger (Hildinger et al., 2001) published 
the expression of T20 in the membrane of target cells as a mechanism to inhibit infection. By 
anchoring T20 in lipid rafts, instead of expressing it unspecifically in the membrane, we are 
allegedly increasing the concentration of the inhibitor in the site of viral entry, since it has 
been well described that HIV-1 uses raft microdomains as entry platforms (Manes et al., 2000; 
Nguyen et al., 2005; Popik et al., 2002), and additionally we are providing further evidence 
for the importance of lipid rafts in HIV-1 infection. The lipid raft-anchored construct will be 
compared with a similar construct localized outside raft microdomains, and both will be tested 
in fusion and infection assays to assess for their inhibitory capacity.
In order to express the T20 peptide at the membrane of the cell, two different T20 
constructs were generated. On one hand, T20LDL was generated by cloning the sequence 
that codifies for the T20 peptide in frame with a short signal peptide, a short sequence of the 
ectodomain, the transmembrane and the juxtamembrane region of the low-density lipoprotein 
receptor (LDLR; this receptor is localized outside lipid rafts), and the cytoplasmic region of 
the CD46 receptor; this construct thus possesses the signals to be anchored in the membrane, 
specifically in a region outside lipid rafts. On the other hand, a T20GPI construct was also 
used, but in this case T20 was already provided in frame with a short signal peptide and the 
sequence that codifies for a glycosylphosphatidylinositol (GPI) anchor (gift from Patrick Keller), 
yielding T20GPI; as was mentioned before, the GPI anchor has the ability to attach proteins to 
the outer leaflet of lipid rafts, and thus T20GPI was used with the intent to be localized in these 
microdomains in the membrane. Both the LDL and the GPI targeting domains were previously 
used to target the CD4 receptor to non-raft and raft membranes, respectively (Del Real et al., 
2002). The aminoacid sequence of the T20 constructs is described in Figure 10.
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Figure 11. T20LDL and T20GPI are expressed at high levels in the membrane of stable cell lines.
T20LDL and T20GPI stable cell lines were stained for T20 expression in the membrane using 2F5 mAb. 
Flow cytometry analysis for stable cell lines produced in HEK-293CD4 cells (A) and in HEK-293T cells 
(B). In both (A) and (B) the percentages relative to positive staining are indicated. 
To generate cells that express membrane-bound T20LDL and T20GPI in a stable manner, 
T20LDL and T20GPI were both cloned in the bicistronic retroviral vector pRV-IRES-GFP and 
then transfected in HEK-293T cells (along with a vector that codifies for a VSVG envelope), in 
order to produce retroviral particles that were further used to infect cell lines. This infection 
induced the insertion of the retroviral genome in the cell’s own DNA and the stable expression 
of the constructs at the membrane of the infected cell. Two different cell lines were used for 
the infection, HEK-293CD4 and HEK-293T, due to specific characteristics that each cell line 
possesses that best suited the following experiments. After infection the cells were stained 
with the 2F5 mAb. To enrich the cell population in T20-expressing cells, sorting was performed 
when less than 70% of cells were positive for T20 expression. Overall, the stable cell lines 
generated had between 70% and almost 100% cells that expressed T20 at the membrane, as 
shown in Figures 11A and 11B.
1.3 Analysis of the localization of T20 constructs
 We used two main approaches to check if each construct was being directed to the 
desired site in the membrane: isolation of detergent-resistant membranes (DRMs) and 
immunofluorescence (copatching) experiments. 
•	 DRM isolation
To perform this experiment, T20LDL- and T20GPI-expressing stable cell lines (HEK-
293CD4) were lysed with Triton X-100 at 4ºC and ultracentrifuged in an Optiprep gradient. 
From the ultracentrifugation 6 different fractions were recovered which contained membrane 
fractions separated by their density. Membranes in the liquid-ordered state are resistant 
to solubilization by non-ionic detergents, such as Triton X-100, and “float” in the density 
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Figure 12. T20GPI partitions in detergent-resistant membranes.
T20LDL and T20GPI stable cell lines (HEK-293CD4) were lysed in the presence of Triton X-100 and ul-
tracentrifuged in an Optiprep gradient. Six fractions were recovered from the ultracentrifugation, and 
fractions 1 and 2 were pooled together for western-blot analysis. Lane 1 corresponds to proteins found 
in detergent-resistant membranes, and lane 5 corresponds to the rest of solubilised proteins. Blotting 
was performed with 2F5 mAb, anti-human transferrin receptor, and anti-caveolin-1.
gradient formed upon centrifugation; as a result, the first two fractions recovered correspond 
to detergent-resistant membranes (DRMs) and are supposedly enriched in raft-associated 
proteins (these two fractions were pooled before assayed by western-blotting); the final fraction 
corresponds to solubilized proteins. In order to detect the localization of each T20 construct, 
the aforementioned 2F5 antibody was used in western-blot assays. The human receptor for 
transferrin was used as a negative control for proteins associated with lipid rafts, located at the 
bottom of the gradient (5th lane; Figure 12), whereas caveolin was used as a positive control 
for proteins associated with raft microdomains, located in the first two fractions (1st lane). 
Unfortunately, the 2F5 antibody recognized an unspecific band at the molecular weight where 
the T20 constructs were expected (around 12 KDa for T20LDL and 8 KDa for T20GPI), but it is 
clear from Figure 12 that a band from T20GPI cell lysates, presumably T20GPI, can be spotted 
in the same lane as the majority of caveolin, which indicates that at least a fraction of T20GPI 
partitions to raft microdomains in the membrane. However, given the unspecificities recognized 
by the 2F5 mAb, no specific band corresponding to the T20LDL protein was distinguished 
(Figure 12); nonetheless,we did not detect any band in the DRM fraction corresponding to 
T20LDL, thus suggesting that this fusion protein does not partition in lipid rafts. No specific 
band for T20 was found in any fraction of HEK-293CD4 control cells either. 
•	 Copatching experiments
To clarify the results gathered from the DRM isolation, an immunofluorescence 
experiment was devised with the T20LDL- and T20GPI-expressing cell lines, in this case 
expressed in HEK-293T cells. This assay is called copatching, and relies on the crosslinking 
of fluorescently-labeled antibodies against raft markers that induces clustering of lipid 
rafts, which can be visualized by confocal microscopy. In the case at hand, the cholera toxin 
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Figure 13. Both T20LDL and T20GPI show the same pattern of colocalization with GM1.
(A) T20LDL and T20GPI stable cell lines (HEK-293T) were stained using 2F5 mAb and CTx, as indicated. 
Patching was induced with fluorescently-labeled secondary antibodies (T20 is shown in blue and GM1 
in red). Colocalization (purple) was analysed by confocal microscopy. (B) Colocalization values were 
obtained for each construct using Image J software. GFPGPI values are shown as comparison and were 
obtained from the experiment described in section Immunofluorescence (copatching) experiments for 
visualization of raft-associated proteins from MATERIALS AND METHODS. Bars indicate the average 
+ SD (n=24 for T20GPI, n=12 for T20LDL and n=14 for GFPGPI). Statistical differences are indicated 
(two-tailed T-student test): *, P<0.05. 
subunit β biotin-coupled protein (CTx) was used to target the ganglioside GM1 found in lipid 
rafts, while the 2F5 antibody was used to detect T20 at the membrane. Fluorescently-labeled 
secondary antibodies were also added to the samples, to induce more crosslinkage and confer 
fluorescence to the cells (an anti-human IgG-Cy5 antibody in the case of T20 and streptavidin-
Cy3 in the case of GM1); therefore, if the protein of interest is located in raft microdomains the 
colocalization signal will be purple, whereas if the proteins segregate in different patches in 
the membrane the fluorescent signals will be either red or blue. The images gathered, shown 
in Figure 13A, showed a mix of raft and non-raft localizations for both T20LDL and T20GPI 
samples, instead of a clear distribution of T20GPI in lipid rafts and T20LDL outside them. 
Consequently, a quantification of T20-GM1 signal colocalization was also performed, using 
the software provided by Image J. The resulting graphic is shown in Figure 13B, where it 
is evident that there is no significant difference in membrane localization between the two 
T20-based constructs. Additionally, the levels of colocalization of a GFPGPI construct with 
GM1 are similar to the ones gathered with the T20 constructs (the GFPGPI data derives from 
another experiment). 
1.4 Effect of membrane-anchored T20LDL and T20GPI in Env-mediated cell-
cell fusion
 The next step taken to analyse the effect of anchoring T20 to the membrane of HIV-
1 target cells was to perform fusion assays. These experiments consist in co-culturing two 
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Figure 14. Membrane-bound T20LDL and T20GPI both inhibit Env-mediated cell-cell fusion.
T20LDL and T20GPI stable cell lines (HEK-293CD4) were cocultured with HEK-293 cells that express 
the HIV-1 Env complex at the membrane. Luciferase relative light units (RLUs), indicative of fusion, 
were obtained for HEK-293CD4 cells (positive control) and are shown as 100% fusion. All other values 
were normalised in accordance. Soluble T20 peptide (several concentrations) and AMD3100 were used 
as inhibitors of Env-mediated cell-cell fusion. Bars indicate average + SD (n=3-6). Statistical differences 
are indicated (two-tailed T-student test), with regard to control cells (293CD4): *, P<0.05; **, P<0.01.
different populations of cells: on one hand, effector cells that are infected with a vaccinia virus 
that induces the expression the gp160Env (IIIB) complex of HIV-1 at the membrane (to mimic 
the virus), and on the other hand target cells that possess the receptors necessary for HIV-1 
entry (in this case CD4 and CXCR4) and are transfected with a reporter gene (luciferase). The 
reporter gene is under the control of a vaccinia virus promoter, and as such the luciferase gene 
will only be expressed if fusion has occurred between the two populations of cells. Besides the 
luciferase reporter gene, the target cells are also transfected with a renilla luciferase plasmid 
that will be expressed constitutively, to serve as an internal control for transfection. To analyse 
the effect of membrane-bound T20 in Env-mediated cell-cell fusion, the target cells for infection 
also express either T20LDL or T20GPI in a stable fashion (stable cell lines produced in HEK-
293CD4 cells); the detection of a luciferase signal will be indicative of the occurrence of fusion 
between the two populations of cells, and will also provide evidence if T20 at the membrane is 
able to inhibit Env-mediated cell-cell fusion.
 The results showed that T20GPI expression in target cells lowers the luciferase signal 
by 70% when compared to the positive control, i.e. HEK-293CD4 cells permissive to HIV-1 
Env-mediated fusion (Figure 14). A more pronounced fusion inhibition was registered for 
cells expressing T20LDL, showing that this construct behaves in a very similar manner to 
T20GPI, although it was presumed to be localised outside lipid rafts. As a control, soluble 
T20 peptide was added externally to control target cells to check the sensitivity of the fusion 
process to T20 in our experimental setup. As expected, the soluble peptide had the ability to 
prevent fusion between the two populations of cells, in a dose-dependent manner (Figure 14). 
The CXCR4-antagonist AMD3100 was also added to HEK-293CD4 cells as another control of 
fusion inhibition, and almost no luciferase signal was detected, confirming that Env-induced 
cell-cell fusion is not an unspecific event but requires a functional CXCR4 coreceptor. 
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1.5 Analysis of the entry of HIV-pseudotypes in T20LDL- and T20GPI-expressing 
cells
 The next step taken was to analyse the ability of membrane-anchored T20 in preventing 
infection of target cells by free viruses. In order to do so, HIV-pseudotypes were generated 
and consequently used to infect cells that express T20 at the membrane. To produce the HIV-
pseudotypes, HEK-293T cells were cotransfected with the pNL4.3lucR-E- vector (described 
in MATERIALS AND METHODS) along with a plasmid that codifies for a given envelope: either 
ADA (an R5 HIV strain), NL4.3 (an X4 HIV strain) or VSVG (control). These pseudotyped 
viruses are replication-deficient, because although they carry the machinery necessary for 
entry into permissive target cells, they lack the genes crucial for the assembly of new viral 
particles. Moreover, they possess the luciferase gene that will be expressed upon entry into the 
target cell; therefore, similarly to the fusion assay, luciferase activity will be used to monitor if 
the viruses are able to enter target cells and if T20 prevents that entry from taking place.
 Once the viruses were produced and titrated for p24 concentration, equal amounts of 
ADA and NL4.3 (30 ng of p24 antigen) were used to infect T20-expressing cells; for VSVG a 
lower concentration was used (8 ng of p24 antigen), since the virus is more effective and the 
luciferase values obtained are several orders of magnitude higher than with the remaining 
viruses. Several infection assays were attempted using HEK-293CD4 T20LDL- and T20GPI-
expressing cells as target cells, but the luciferase levels were too low for the results to be taken 
into consideration. 
We therefore decided to use TZM-b1 cells, a HeLa-derived cell line that expresses high 
levels of CD4, CCR5 and CXCR4 and is commonly used in X4 and R5 infection experiments; 
since we did not have TZM-b1 cells that stably expressed T20 at the membrane, we performed 
infection experiments with TZM-b1 transiently expressing T20LDL or T20GPI constructs. 
The transfection efficiency is shown in Figure 15A, where around 23% of cells were positive 
for T20 expression in the membrane, both in the case of T20LDL and T20GPI. The infection 
assay (Figure 15B) indicated that the expression of T20LDL or T20GPI at the membrane of 
target cells scarcely affects the entry of ADA viruses (no infection was obtained with NL4.3 
pseudotypes). However, the entry of VSVG viruses was inhibited by the membrane-anchored 
peptide. As a control, TZM-b1 cells were also incubated with three different concentrations 
of soluble T20 peptide (2, 5 and 10 µg/mL) 24h before infection (and renewed upon it), and 
it was confirmed that the peptide inhibited the entry of the ADA virus in a dose-dependent 
manner; furthermore, the cells incubated with soluble T20 were permissive for VSVG entry, as 
expected.
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Figure 15. Transient expression of T20LDL and T20GPI at the membrane does not inhibit infection by 
free HIV-1 pseudotyped viruses.
(A) Flow cytometry analysis of TZM-b1 cells transiently expressing T20LDL or T20GPI. The percent-
ages relative to positive staining for 2F5 mAb are indicated. (B) TZM-b1 cells transiently expressing 
T20LDL or T20GPI were infected with HIV-1 replication-deficient viruses pseudotyped with ADA or 
VSVG envelopes. Luciferase values, indicative of infection, were obtained for TZM-b1 cells (positive 
control) and are shown as 100% infection. All other values were normalised in accordance. Soluble T20 
peptide (several concentrations) was used as inhibitor of HIV-1 infection. Bars indicate average + SD 
(n=2). Statistical differences are indicated (two-tailed T-student test), with regard to control cells (TZM-
b1): *, P<0.05; **, P<0.01.
1.6 Analysis of the infectivity of HIV-pseudotypes produced in T20LDL- and 
T20GPI-expressing cells 
 We next investigated whether the incorporation of T20 in the envelope of emerging 
virions alters their infectivity; since newly-formed viral particles presumably exit the cell 
through lipid rafts (Nguyen and Hildreth, 2000), indeed incorporating characteristic cell proteins 
in their envelope (Arthur et al., 12), we postulated that T20GPI will also be incorporated in 
the viral envelope upon exit. We therefore analysed if the presence of this T20 construct in the 
viral envelope would decrease the ability of those viral particles to engage a new target cell 
and initiate a new fusion process.
In order to test such hypothesis, HIV-pseudotypes were produced in T20-expressing 
cells. In this case, three viral envelopes were used in addition to the ones mentioned before: 
ADA 38E/42S (with a two-aminoacid substitution that confers resistance to T20-mediated 
inhibition), ADA 38A/42T (another two-aminoacid substitution conferring resistance to T20), 
and NL4.3 38E/42S (the same aminoacid substitution as ADA 38E/42S). The plasmids that 
codify for these envelopes were kindly provided by Rafael Delgado. The HIV-pseudotypes 
were produced in T20LDL- and T20GPI-expressing stable cell lines (HEK-293T), titrated for 
p24 concentration, and used in infection assays with TZM-b1 cells as targets of infection. 
Additionally, viruses produced in HEK-293T cells were also used as a positive control. 
 First, we analysed the susceptibility of the different pseudotypes produced in HEK-
293T cells to T20-mediated inhibition (Figure 16A). The data obtained shows that, while the 
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Figure 16. HIV-pseudotypes produced in T20LDL- and T20GPI-expressing cells are more infectious 
than viruses produced in control cells.
(A) HIV-1 replication-deficient viruses pseudotyped with ADA, ADA 38E/42S, ADA 38A/42T, NL4.3, 
NL4.3 38E/42S or VSVG envelopes were infected in TZM-b1 cells in presence of 0, 2, 5 or 10 μg/mL of 
soluble T20 peptide. Luciferase levels, indicative of infection, were obtained for TZM-b1 cells (control) 
and are shown as 100% infection. All other values were normalised in accordance. Bars indicate aver-
age + SD (n=2) (B) HIV-1 replication-deficient viruses pseudotyped with ADA, ADA 38E/42S, ADA 
38A/42T, NL4.3 or VSVG envelopes were produced in T20LDL and T20GPI stable cell lines (HEK-293T) 
and used to infect TZM-b1 cells. Luciferase values, indicative of infection, were obtained for viruses 
produced in HEK-293T cells (positive control) and are shown as 100% infection. All other values were 
normalised in accordance. Bars indicate average + SD (n=2). Statistical differences are indicated (two-
tailed T-student test), with regard to control cells (TZM-b1), in (A), or control viruses (produced in 293T 
cells) in (B): *, P<0.05; **, P<0.01.
ADA wildtype viruses are sensitive to T20-mediated inhibition, as would be expected, the 
NL4.3 are not. Furthermore, the two-aminoacid substitutions that were introduced in the ADA 
and NL4.3 envelopes to confer resistance to T20 behave differently: the 38E/42S combination 
seems to be relatively resistant to T20-mediated inhibition in ADA-pseudotyped envelopes, 
although 40% of inhibition was obtained at a T20 dosage of 10 µg/mL (Figure 16A). Given the 
resistance of the NL4.3 wildtype envelope to T20 inhibition, it is not surprising that the NL4.3 
38E/42S mutant envelope would be totally resistant to the inhibitor at the dosage used. The 
introduction of the double 38A/42T mutation in the ADA envelope confers no resistance at 
all, in spite that these mutations were reported to prevent T20-mediated inhibition (Mink et al., 
2005; Sista et al., 2004; Wei et al., 2002). As a control, VSVG viruses were also used in this assay 
and no change in infection with T20 incubation was registered, as would be expected. 
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In Figure 16B are shown the different HIV-pseudotypes produced in either HEK-293T, 
T20LDL-expressing or T20GPI-expressing cells. The data indicates that all ADA strains used, 
when produced in cells that express T20 at the membrane, are several orders of magnitude 
more infectious than the same strains produced in control cells. Intriguingly, the same does 
not happen with the NL4.3 strain, which only showed a mild increase in infectivity when 
produced in T20GPI-expressing cells (Figure 16A). Once again, VSVG pseudotypes were used 
as a control and no difference in infectivity was detected between viruses produced in HEK-
293T cells or T20-expressing cells. 
Overexpression of either T20LDL or T20GPI at the membrane of target cells is able to inhibit 
X4 Env-mediated cell-cell fusion. Transient low expression of T20 at the membrane of target 
cells is not sufficient to inhibit entry of ADA pseudotypes. ADA pseudotypes produced in 
T20LDL- and T20GPI-expressing cells are more infectious than wildtype viruses.
2. Effect of the inhibition of dihydroceramide desaturase (DHCDase) 
in HIV-1 infection   
Previous studies pointed out glycosphingolipids as key elements involved in the HIV-
1 Env-mediated fusion process (Hammache et al., 1; Harouse et al., 11; Hug et al., 2000; 
Nehete et al., 2002; Puri et al., 2004) These evidences prompted us to study the effect on HIV-
1 infection of a novel inhibitor in the sphingolipid pathway, GT11, developed by Gemma 
Fabriàs laboratory at the IIQAB in Barcelona (Triola et al., 2001). This compound is a ceramide 
analog that inhibits the enzyme dihydroceramide desaturase (DHCDase), responsible for the 
formation of a 4,5-trans-double bond in dihydroceramide that converts it to ceramide (Triola et 
al., 2004; Triola et al., 2001). Although GT11 does not prevent the formation of sphingolipids in 
the cell, the ones that are formed possess a dihydroceramide backbone instead of a ceramide 
one, which alters their biophysical and structural properties (Contreras et al., 2005). Therefore, 
treatment of cells with GT11 would induce an accumulation of saturated sphingolipids in lipid 
rafts; how this accumulation will affect lipid raft properties and function is not known, and 
we decided to study this subject using HIV-1 infection as a biological model. Our purpose is to 
better understand the implication of interfering with ceramide synthesis in cells.
Two different GT11 compounds are used in this approach: GT11 C8 (with a fatty acid 
chain composed by 8 carbons) and GT11pyr (a derivative of the original GT11 compound, with 
a pyrimidine ring) (Figure 1). The GT11pyr inhibitor was characterized more thoroughly and 
used in more assays because its pyrimidine ring confers it hydrosolubility, an advantage in in 
vivo studies. Both compounds have been tested in Dr. Fabriàs laboratory for inhibitory activity 
against DHCDase, and the IC50 values found for each one were 23 nM for GT11 C8 (Triola et al., 
2004) and 27 µM for GT11pyr (unpublished data). 
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Figure 1. Chemical structure of GT11 C8 and GT11pyr.
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2.1 Viability and cell cycle analyses in GT11-treated cells
 To study if the compounds are well tolerated by cells, both GT11 C8 and GT11pyr were 
used in viability assays based on Trypan Blue dye exclusion method, and additionally the cells 
were stained for cell cycle analysis using propidium iodide. HEK-293, Jurkat and peripheral 
blood mononuclear cells (PBMCs) were used in these assays. According to the IC50 values 
reported for each inhibitor in in vitro assays, different concentration ranges were used, higher 
for GT11pyr than for GT11 C8.
 In the case of GT11 C8, PBMCs were stimulated in vitro with PHA-L for 24h and further 
maintained in culture in the presence of IL-2. Cells were treated with several concentrations 
of GT11 C8 (0, 0.1, 0.5, 1 and 2 µM) for three consecutive days, counted everyday and stained 
with DNA Prep for cell cycle analysis. The data obtained from the experiment is shown in 
Figure 18A, where it is evident that GT11 C8 treatment is not detrimental to the cells, since 
there is no significant difference in cell number between cells incubated with the inhibitor 
and control cells. Noteworthy is the fact that, at least 24h after the start of the incubation with 
the compound, concentrations higher than 0,5 µM of GT11 C8 increased cell growth when 
compared with vehicle-treated cells. Staining with propidium iodide, however, showed no 
differences in all cell cycle phases for the last time point (Figure 18B). These results suggest 
that the compound is well tolerated by PBMCs, at least until 2 µM.
 In the case of GT11pyr, PBMCs were stimulated in vitro with PHA-L for 24h and further 
maintained in culture in the presence of IL-2. Cells were treated with several concentrations 
of GT11pyr (0, 0.5, 1, 2, 5 or 10 µM) for three consecutive days, counted everyday and stained 
with DNA Prep for cell cycle analysis. The results are depicted in Figure 1, both for cell 
number (Figure 1A) and flow cytometry analysis of cell cycle (Figure 1B). The data shows 
that cell growth is affected by GT11pyr concentrations higher than 5 µM, and, accordingly, 
cell cycle measurements show that both 5 and 10 µM of GT11pyr slightly increase the number 
of apoptotic cells, for the last day assayed. Lower concentrations of the compound are less 
harmful to the cells. A similar analysis was performed with Jurkat cells, incubated with either 
0, 1, 2, 5, 10 or 15 µM of GT11pyr. The results (Figure 20) show that GT11pyr concentrations 
higher than 5 µM also affect cell growth (Figure 20A), although lower concentrations are well 
tolerated by cells. Furthermore, cell cycle analysis (Figure 20B) confirms that the number of 
apoptotic cells increases proportionally with GT11pyr incubation.
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Figure 18. GT11 C8 does not affect the viability of PBMCs.
Activated PBMCs were incubated with 0, 0.1, 0.5, 1 or 2 μM of GT11 C8 for 3 consecutive days. (A) Cells 
were counted every day using Trypan Blue exclusion method. Shown is average ± SD (n=2). (B) Cells 
were stained with propidium iodide and cell cycle was analysed by flow cytometry. Shown is last day of 
incubation for each of the concentrations used. The percentage of cells in each cycle is indicated.
time post-treatment (h)
0
ce
ll
 n
um
be
r
0.1 µM GT11 C8
0 µM GT11 C8 (vehicle)
2 µM GT11 C8
1 µM GT11 C8
0.5 µM GT11 C8
5×105
1×106
1.5×106
2×106
2.5×106
3×106
3.5×106
4×106
4.5×106
0
B
A
24 48 72
0 µM 
GT11pyr
0.1 µM 
GT11pyr
0.5 µM 
GT11pyr
1 µM 
GT11pyr
2 µM 
GT11pyr
1023
Fluorescence intensity
0
C
el
l c
ou
nt
0
G0/G1
53.1%
Synthesis
4.9%
G2/M
0.8%
Death
42.3%
Apoptosis
28.6%
G0/G1
53.9%
Synthesis
5.7%
G2/M
1.1%
Death
40.5%
Apoptosis
26.5%
1023
Fluorescence intensity
0
C
el
l c
ou
nt
0
G0/G1
59.7%
Synthesis
3.1%
G2/M
1.7%
Death
36.7%
Apoptosis
24.1%
1023
Fluorescence intensity
0
C
el
l c
ou
nt
0
G0/G1
55.3%
Synthesis
3.4%
G2/M
2.0%
Death
41.3%
Apoptosis
28.0%
1023
Fluorescence intensity
0
C
el
l c
ou
nt
0
G0/G1
54.2%
Synthesis
3.5%
G2/M
1.6%
Death
42.4%
Apoptosis
28.0%
1023
Fluorescence intensity
0
C
el
l c
ou
nt
0
In summary, these experiments indicate that the inhibitors GT11 C8 and GT11pyr have 
different toxicity on target cells. On one hand, GT11 C8 seems to be better tolerated by PBMCs, 
with little or no detrimental effect registered in these cells at the highest concentration used (2 
µM). On the other hand, GT11pyr is more harmful, although concentrations lower than 5 µM 
are well tolerated by target cells.
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Figure 1. GT11pyr is toxic over 5 μM for PBMCs.
Activated PBMCs were incubated with 0, 0.5, 1, 2, 5 and 10 μM of GT11pyr for 3 consecutive days. (A) 
Cells were counted every day using Trypan Blue exclusion method. (B) Cells were stained with propid-
ium iodide and cell cycle was analysed by flow cytometry. Shown is last day of incubation for each of 
the concentrations used. The percentage of cells in each cycle is indicated.
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Figure 20. GT11pyr is toxic over 5 μM for Jurkat cells.
Jurkat cells were incubated with 0, 1, 2, 5, 10, and 15 μM of GT11pyr for 3 consecutive days. (A) Cells 
were counted every day using Trypan Blue exclusion method. (B) Cells were stained with propidium 
iodide and cell cycle was analysed by flow cytometry. Shown is last day of incubation for each of the 
concentrations used. The percentage of cells in each cycle is indicated.
72
time post-treatment (h)
0
ce
ll
 n
um
be
r
2×106
4×106
6×106
8×106
1×107
0 24 48
1.2×107
1 µM GT11pyr
0 µM GT11pyr
10 µM GT11pyr
5 µM GT11pyr
2 µM GT11pyr
15 µM GT11pyr
A
B
G0/G1
51.9%
Synthesis
27.1%
G2/M
20.9%
Death
0.9%
Apoptosis
0.8%
0 µM 
GT11pyr
1 µM 
GT11pyr
2 µM 
GT11pyr
5 µM 
GT11pyr
10 µM 
GT11pyr
15 µM 
GT11pyr
1023
Fluorescence intensity
0
C
el
l c
ou
nt
0
1023
Fluorescence intensity
0
C
el
l c
ou
nt
0
G0/G1
55.1%
Synthesis
24.3%
G2/M
19.2%
Death
1.9%
Apoptosis
1.6%
1023
Fluorescence intensity
0
C
el
l c
ou
nt
0
G0/G1
53.8%
Synthesis
23.2%
G2/M
20.1%
Death
3.5%
Apoptosis
2.7%
1023
Fluorescence intensity
0
C
el
l c
ou
nt
0
G0/G1
53.8%
Synthesis
21.1%
G2/M
18.8%
Death
6.7%
Apoptosis
5.2%
1023
Fluorescence intensity
0
C
el
l c
ou
nt
0
G0/G1
53.4%
Synthesis
18.9%
G2/M
17.7%
Death
10.8%
Apoptosis
8.5%
1023
Fluorescence intensity
0
C
el
l c
ou
nt
0
G0/G1
48.5%
Synthesis
16.0%
G2/M
13.2%
Death
23.1%
Apoptosis
17.3%
2.2 Effect of GT11 on Env-mediated cell-cell fusion
 In order to analyse whether GT11 has the ability to inhibit the entry of HIV-1 in the 
cell, Env-mediated cell-cell fusion assays were performed. The experiment is similar to the 
one described in section 2.1, but in this case target cells (HEK-293CD4) were incubated with 0, 
0.01, 0.1, 0.5, 1, 5 or 10 µM of GT11 C8 for 24h before fusion, and renewed upon it. The results, 
depicted in Figure 21, show that there is a dose-dependent decrease in the luciferase signal 
when the cells are incubated with GT11 C8. Moreover, the estimated IC50 of GT11 C8 for this 
assay is 0.08 µM. This result indicates that this compound is able to inhibit Env-mediated cell-
cell fusion at low concentrations. 
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Figure 21. GT11 C8 inhibits Env-mediated 
cell-cell fusion in a dose-dependent manner.
HEK-293CD4 cells were incubated with 0, 0.01, 
0.1, 0.5, 1, 5 or 10 μM of GT11 C8 for 24h and 
cocultured with HEK-293 cells that express the 
HIV-1 Env complex at the membrane. Luci-
ferase relative light units (RLUs), indicative of 
fusion, were normalised using the values ob-
tained for HEK-293 cells (negative control) and 
are shown as fold increase in fusion. Shown is 
average ± SD (n=2).
2.3 Analysis of the entry of HIV-pseudotypes in GT11-treated cells
 The next step taken was to analyse if GT11 is able to prevent infection of target cells by 
free viruses. Two different experiments were devised, in one case incubating target cells with 
high concentrations of GT11pyr for a short period of time, and in the other case using low 
concentrations of the compound over several days. In both cases, viral particles were produced 
by cotransfecting HEK-293T cells with the pNL4.3lucR-E- vector (described in MATERIALS AND 
METHODS) and a vector that codifies for a given viral envelope: ADA (R5 HIV strain), NL4.3 
(X4 HIV strain) or VSVG (control). The pseudotyped viruses were titrated and equal amounts 
of p24 antigen were then used to infect GT11pyr-treated and control cells. 
 In the first approach mentioned, TZM-b1 cells were incubated with either 0, 15, 20 or 30 
µM of GT11pyr for 24h before viral supernatants corresponding to 45 ng of p24 antigen were 
added to the cells for an additional 24h at 37ºC (GT11pyr incubation was maintained but not 
renewed). Moreover, citotoxicity assays indicated that the LD50 of the compound, for TZM-b1 
cells, was 35 µM. The results, presented in Figure 22A, show that whereas the VSVG viruses 
are able to enter target cells at all concentrations tested, the entry of HIV-derived pseudotypes 
(both ADA and NL4.3) is significantly reduced. Concentrations of 15 µM upwards induce at 
least a 60% inhibition in viral entry for both ADA and NL4.3, but not for VSVG. This suggests 
that, by altering the lipid composition of lipid rafts using GT11pyr, the entry of HIV-based 
viral pseudotypes is specifically affected, when compared with a control virus (VSVG) that 
enters the cell through an endocytic pathway (Johannsdottir et al., 2008). 
 In the second type of experiment performed, TZM-b1 cells were incubated with 0, 0.5, 1, 
1.5 or 2 µM of GT11pyr for 36h, 60h or 84h before infection. Viral supernatants corresponding to 
25 ng of p24 antigen were added to the cells for 24h at 37ºC (GT11pyr incubation was maintained 
but not renewed), and the results of the infection are shown in Figure 22B. As opposed to the 
results presented in Figure 22A, where at 24h post-treatment the effect in ADA and NL4.3 
entry was already evident, when lower concentrations of GT11pyr are used the cells have to be 
in contact with the inhibitor for longer periods of time for an effect to be seen. In more detail, 
at 36h post-treatment there is no significant difference between ADA and VSVG entry in target 
cells, nor is there at 60h post-treatment. However, when the cells were incubated for 84h with 
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Figure 22. GT11pyr inhibits infection by free HIV-1 pseudotyped viruses.
(A) TZM-b1 cells incubated with 0, 15, 20 or 30 μM of GT11pyr for 24h were infected with HIV-1 replica-
tion-deficient viruses pseudotyped with ADA, NL4.3 or VSVG envelopes. Luciferase values, indicative 
of infection, were obtained for TZM-b1 cells (positive control) and are shown as 100% infection. All 
other values were normalised in accordance. (B) TZM-b1 cells incubated with 0, 0.5, 1, 1.5 or 2 μM of 
GT11pyr for 36h, 60h or 84h were infected with HIV-1 replication-deficient viruses pseudotyped with 
ADA or VSVG envelopes. Luciferase values, indicative of infection, were obtained for TZM-b1 cells 
(positive control) and are shown as 100% infection. All other values were normalised in accordance. 
Shown is average ± SD (n=2).
GT11pyr, the entry of ADA viruses is significantly reduced when compared to VSVG viruses, 
for all concentrations tested. This indicates that, when lower concentrations of GT11pyr are 
used (until 2 µM), longer periods of incubation are needed for an effect to be seen. 
The infection results indicate that GT11pyr is able to specifically inhibit the entry of HIV-
pseudotypes, in a dose-dependent manner. High concentrations of the compound produce a 
more drastic inhibition effect, whereas lower concentrations need longer incubation periods 
to inhibit the entry of these viruses. Furthermore, the entry of the VSVG virus, a non-lipid raft 
associated virus, is not affected by GT11pyr treatment. 
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2.4 Effect of GT11 on T cell chemotaxis and activation
 We next addressed the question of whether GT11 C8 and GT11pyr interfere with 
chemotaxis and T cell activation, two processes in which lipid rafts play a major role (Lin et al., 
1; Manes et al., 1; Zhang et al., 18b), at the concentrations at which these compounds 
inhibited HIV-1 infection. 
•	 Chemotaxis assays
An important characteristic of lymphocytes is the ability to migrate in response to a 
chemotactic gradient. To test whether blockade of DHCDase activity affects the chemotactic 
ability T cells, Jurkat cells and PBMCs were incubated with several concentrations of either 
GT11 C8 or GT11pyr and assayed for CXCR4-mediated chemotaxis in a modified Boyden 
chamber assay. In this type of experiment, cells are placed in the upper of two separate 
compartments communicated by a porous membrane, while in the lower compartment 
medium the appropriate chemokine is placed. After an incubation period of around 3-4 hours 
(depending on the cell line, explained in MATERIALS AND METHODS), the cells that have passed 
from the upper to the lower chamber are counted and represent the cells that have migrated in 
response to the chemotactic gradient. 
 The results, shown in Figure 23, indicate the amount of cells that have migrated in 
response to either complete medium or basal medium + CXCL12, when compared to basal 
medium alone, which represents background migration. In Figure 23A Jurkat cells were 
incubated with either 0.2 or 2 µM of GT11 C8. We found no differences in the chemotactic index 
when cells were incubated with vehicle or 0.2 µM of GT11 C8; surprinsingly, we observed 
a pronounced increase in the CXCL12-induced chemotaxis (more than 100 times over basal 
medium) when the cells were incubated with GT11 C8 at 2 µM. Interestingly, this increase was 
not observed when fetal calf serum (FCS) was used as chemoattractant, suggesting that GT11 
C8 enhanced CXCL12-induced chemotaxis in a specific manner. We also found that GT11pyr 
did not substantially affect CXCL12- or FCS-induced chemotaxis of Jurkat cells in the 1 to 5 
µM dosage range (Figure 23B). Nonetheless, we found again a specific amplification of the 
CXCL12-induced chemotaxis (10 times) when the cells were incubated with GT11pyr at 10 
µM, a concentration that affected Jurkat cell growth (Figure 20A). As for PBMCs incubated 
with 0, 0.5, 1, 2 or 5 µM of GT11pyr, the results show a less pronounced increase in migration 
with GT11pyr incubation than the one registered with Jurkat cells (Figure 23C). Increasing 
concentrations of the inhibitor induce migration in response to CXCL12, but such migration 
only increases from 1.5 times over basal medium for control cells to 5.5 times over basal 
medium for cells incubated with 5 µM of GT11pyr. 
RESULTS
-82-
Migration index
0 20 40
2 µM GT11 C8
0.2 µM GT11 C8
0 µM GT11 C8 (vehicle)
complete
medium
basal medium 
+ SDF-1
Migration index
0 5 10 15 20
2 µM GT11pyr
1 µM GT11pyr
0 µM GT11pyrcomplete
medium
basal medium 
+ SDF-1
10 µM GT11pyr
5 µM GT11pyr
Migration index
1 µM GT11pyr
0.5 µM GT11pyr
0 µM GT11pyr
complete
medium
basal medium 
+ SDF-1
5 µM GT11pyr
2 µM GT11pyr
0 1 2 3 4 5 6
A
B
C
100 120
**
**
*
*
**
**
*
*
*
Figure 23. GT11 C8 and GT11pyr do not inhibit T cell chemotaxis.
(A) Jurkat cells were incubated with 0, 0.2 or 2 μM of GT11 C8 for 24h and placed in modified Boyden 
chambers to determine migratory response to the chemokine CXCL12. Migration index corresponds to 
the number of cells that migrated in response to fetal calf serum (FCS) or CXCL12 normalised with the 
corresponding number of cells that migrated in basal medium. Bars indicate average + SD (n=2). (B) 
Jurkat cells were incubated with 0, 1, 2, 5 or 10 μM of GT11pyr for 24h and the same type of analysis as 
in (A) was performed. Bars indicate average + SD (n=4). (C) PBMCs were incubated with 0, 0.5, 1, 2 or 
5 μM of GT11pyr for 27h and the same type of analysis as in (A) was performed. Bars indicate average 
+ SD (n=2). Statistical differences are indicated (two-tailed T-student test), with regard to control cells (0 
μM of GT11pyr): *, P<0.05; **, P<0.01.
•	 IFNγ production
 Additionally, PBMCs were analised for the ability to become activated and produce 
IFNγ in the presence of GT11pyr. This is an important feature of T-lymphocytes and it is crucial 
to determine if incubation with the inhibitor does not impair the cells in their capacity to become 
activated in the presence of stimulatory factors. PBMCs were incubated with either 0, 0.5, 1, 
2, 5, or 10 µM of GT11pyr, in complete medium without serum nor IL-2, in order to prevent 
unspecific activation. Following incubation with the inhibitor, the cells were stimulated with 
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Figure 24. GT11pyr does not inhibit IFNγ pro-
duction by PBMCs.
Non-stimulated PBMCs were incubated with 0, 
0.5, 1, 2, 5, or 10 μM of GT11pyr for 36h at 37ºC. 
IFNγ was quantified in cell supernatants after 
activation with anti-CD3 and anti-CD28 anti-
bodies for 12h. Bars indicate average + SD (n=2). 
Statistical differences are indicated (two-tailed 
T-student test), with regard to control cells (0 μM 
of GT11pyr): *, P<0.05; **, P<0.01.
anti-CD3 and anti-CD28 antibodies, still in the presence of the inhibitor, and the amount of 
IFNγ produced following stimulation was quantified by ELISA. The results, shown in Figure 
24, indicate that incubation of the cells with low concentrations of GT11pyr is able to increase 
the production of IFNγ, although for higher concentrations (10 µM) the values revert to the 
control ones. More importantly, no inhibition or decrease of IFNγ output was detected with 
GT11pyr incubation.
In summary, our results indicate that GT11 C8 and GT11pyr, at concentrations interfering 
with HIV-1 infection, do not prevent other raft-associated processes in HIV-1 target cells, such 
as chemotaxis and TCR-mediated activation. 
2.5 Analysis of the lipid composition of detergent-resistant membranes (DRMs) 
in GT11-treated cells
We next analysed whether GT11 treatment alters the lipid composition of raft 
microdomains. DRMs were isolated from HEK-293CD4 cells (see section 1.3) pre-treated with 
GT11pyr at 15, 30 or 60 µM for 24h. In these conditions, GT11pyr treatment showed minor effects 
on HEK-293 viability, with the exception of the highest concentration of the compound (Figure 
25A). The lipid composition of the DRMs was analysed in Dr. Fabriàs laboratory using High 
Performance Liquid Chromatography (HPLC) coupled to time of fly (TOF) mass spectrometry 
(HPLC-MS), and using C16 sphingomyelin as a probe, since this lipid is very abundant in 
lipid rafts. The resulting chromatograms from fractions that correspond to DRMs are shown in 
Figure 25B. It was found that GT11pyr treatment promoted a decrease in the relative amount 
of sphingomyelin (SM), which paralleled an increase in the amount of dihydrosphingomyelin 
(dhSM) in the DRM fraction. This change in the dhSM/SM ratio was dependent of the GT11pyr 
dosage used, reaching a maximum of 30% at a GT11pyr concentration of 30 µM (Figure 25C). 
The highest concentration of GT11pyr tested (60 µM) did not increase the dhSM/SM ratio, 
most likely because the compound is toxic for cells at this dosage. These results are consistent 
with a GT11pyr-induced inhibition of dihydroceramide desaturase in vivo, thus causing the 
accumulation of dihydrosphingolipids in lipid rafts.
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Figure 25. GT11pyr induces a replacement of SM for dhSM in lipid rafts.
(A) HEK-293 cells were incubated with 0, 15, 30 or 60 μM of GT11pyr for 3 consecutive days. Cells were 
counted every day using Trypan Blue exclusion method. Shown is average ± SD (n=2). (B) HEK-293CD4 
cells were incubated with 0, 15, 30 or 60 μM of GT11pyr for 24h, lysed in the presence of Triton X-100 
and ultracentrifuged in an Optiprep gradient. Six fractions were recovered from the ultracentrifugation 
and analysed by HPLC-MS. Chromatograms relative to the first fraction (DRMs) are shown for the con-
trol and 30 μM samples. (C) dhSM and SM were quantified for each sample and the dhSM/SM ratio is 
indicated for each concentration assayed. Shown is average ± SD (n=2). 
2.6 Analysis of the protein composition in lipid rafts
 We next analysed whether GT11-induced changes in the lipid composition of lipid rafts 
affected the preferential partitioning of specific membrane proteins into these microdomains. 
•	 DRM isolation
The same fractions from the ultracentrifugation used for the analysis of the lipid 
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Figure 26. GT11pyr does not affect CD4 partitioning in detergent-resistant membranes.
(A) HEK-293CD4 cells were incubated with 0, 15, 30 or 60 μM of GT11pyr for 24h, lysed in the pres-
ence of Triton X-100 and ultracentrifuged in an Optiprep gradient. Six fractions were recovered from 
the ultracentrifugation, and fractions 1 and 2 were pooled together for western-blot analysis. Lane 1 
corresponds to proteins found in detergent-resistant membranes, and lane 5 corresponds to the rest of 
solubilised proteins. Blotting was performed with anti-CD4 receptor, anti-human transferrin receptor, 
and anti-caveolin-1. (B) In the case of the CD4 receptor, band quantification was performed for each 
fraction.
composition described in section 2.5 were also employed to analyse the partitioning of the CD4 
receptor by western-blot, as well as controls for DRM-associated and DRM-excluded proteins. 
The results are depicted in Figure 26, showing the comparison between the concentration 
of GT11pyr that promoted the maximal dhSM/SM ratio (30 µM; Figure 25C), and control 
cells. No difference in CD4 localization is detected between control cells and cells incubated 
with the inhibitor. As previously reported, the CD4 receptor was distributed between the 
DRM fraction (1st lane) and the fraction corresponding to solubilized membrane proteins (5th 
lane); this distribution was not altered by GT11pyr incubation (Figure 26A and B). The unique 
partitioning of caveolin and of the transferrin receptor, used as controls for DRM-associated 
and DRM-excluded membrane proteins, indicated the quality of the gradients. 
•	 Copatching experiments
To test if GT11pyr incubation is able to affect the membrane localization of raft-
associated proteins, HEK-293CD4 cells were incubated with either 0 or 60 µM of GT11pyr 
and an immunofluorescence assay was performed, similar to the one detailed in section 1.2. 
The cells were also transfected with a vector encoding for a GFPGPI construct, as a positive 
control for raft-associated proteins. After a 24h-incubation period with the inhibitor, both 
treated and non-treated cells (control) and GFPGPI-transfected and non-transfected cells 
were placed in fibronectin-coated chambers for an additional 4h, in the presence of GT11pyr. 
Afterwards, primary antibodies against GM1, CD4, CXCR4 or GFP were added to the samples, 
followed by secondary fluorescently-labeled antibodies to induce patching of these proteins 
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Figure 2. GT11pyr does not alter CD4, CXCR4 and GFPGPI colocalization with GM1.
(A) HEK-293CD4 cells were transfected with GFPGPI and incubated with 0 or 60 μM of GT11pyr for 
24h. Cells were stained using anti-CD4, anti-CXCR4, anti-GFP and CTx, as indicated. Patching was in-
duced with fluorescently-labeled secondary antibodies (CD4, CXCR4 and GFPGPI are shown in green 
and GM1 in red). Colocalization (yellow) was analysed by confocal microscopy. (B) Colocalization val-
ues were obtained for each staining using Image J software. Bars indicate average + SD (n=8-14 depend-
ing on the sample).
at the membrane of the cells. Once again, CTx was used to label lipid raft-based GM1, and the 
colocalization of the aforementioned proteins with the fluorescent signal detected for GM1 
gave an indication of whether the proteins were found in lipid rafts or not.
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Figure 2 shows an assortment of confocal images for each of the conditions used 
(Figure 2A), representative of the total of images processed (in red is always shown GM1, and 
in green either CD4, CXCR4 or GFPGPI, as indicated), and a graphic with the quantification 
of CD4-GM1, CXCR4-GM1 and GFPGPI-GM1 signal colocalization (Figure 2B), in order to 
clarify the situation of each protein regarding lipid rafts. When comparing the colocalization 
of each protein with GM1 in basal conditions (without GT11pyr) and in cells incubated with 
60 µM of GT11pyr, the percentages indicate that there was no significant difference for neither 
the CD4 receptor, the CXCR4 receptor or the GFPGPI protein (Figure 2B). This suggests 
that treatment with 60 µM of GT11pyr does not alter the localization of these raft-associated 
proteins, which is consistent with the DRM protein analysis showed above (Figure 26). 
Interestingly, the colocalization values obtained for CXCR4 are lower than the ones obtained 
for the remaining proteins, suggesting that the partition coefficient of this receptor into lipid 
rafts is lower than that of the CD4 receptor, in non-stimulated conditions. This agrees with 
previous reports showing that CXCR4 partitioning into lipid rafts changes upon stimulation 
(Manes et al., 2000).
2. Analysis of the effect of dihydrosphingomyelin in lipid membranes
The results detailed above showed that GT11pyr induced changes in the lipid 
composition of the cell membrane, but did not affected the association of HIV-1 receptors to 
lipid rafts. To better understand the biological implication of changing the composition of 
lipid rafts from SM to dhSM, Felix Goñi laboratory at the UPV/EHV in Bilbao studied the 
biophysical properties of dhSM in lipid bilayers of different composition. 
•	 Negative curvature structures
Since the occurrence of fusion between the viral and the cellular membranes requires 
the formation of a negative curvature structure, the effect of dhSM on the lamellar-inverted 
hexagonal phase transition of dielaidoylphosphatidylethanolamine (DEPE) model membranes 
was assessed. In Figure 28A are shown the thermograms relative to the lamellar-inverted 
hexagonal transitions of different DEPE-dhSM mixtures, and it is evident that with increasing 
concentrations of dhSM the transition temperature rises. This suggests that the presence 
of dhSM difficults the formation of negative curvature structures. In Figure 28B the same 
analysis was performed but with more complex mixtures of lipids: DEPE-5%dhSM, DEPE-
5%SM, DEPE-5%dhSM:cholesterol(Ch) (1:1), DEPE-5%SM:Ch (1:1) and DEPE-5%SM:dhSM:
Ch (0.7:0.3:1). The results show that both SM and dhSM induced a roughly similar increase in 
the transition temperatures in DEPE bilayers. Furthermore, the replacement of SM for dhSM 
did not change the transition temperature, suggesting that the substitution of one lipid by the 
other does not affect the formation of negative curvature structures. 
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Figure 28. Replacement of SM for dhSM does not affect the formation of negative curvature structures 
in lipid bilayers.
(A) DSC thermograms relative to lamellar-inverted hexagonal transitions of DEPE and DEPE-dhSM 
mixtures in aqueous solution. The concentration of DEPE is constant (4 mM). (B) DSC thermograms 
relative to lamellar-inverted hexagonal transitions of different mixtures of DEPE, dhSM, SM and Ch in 
aqueous solution. The concentration of DEPE is constant (4 mM).
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Figure 2. Replacement of SM for dhSM increases membrane rigidity in lipid bilayers.
Generalised polarization of Laurdan-labeled membranes with different SM, dhSM and Ch mixtures. 
•	 Membrane rigidity
Another possible effect of modifying the lipid composition of the membrane is the 
alteration of membrane rigidity. In order to test it, the generalised polarization of Laurdan-
labeled membranes was used to assess membrane fluidity in SM:Ch (1:1), SM:dhSM:Ch 
(0.7:0.3:1), SM:dhSM:Ch (0.5:0.5:1) and dhSM:Ch (1:1) mixtures. The results, shown in Figure 
2, indicate a progressive increase in generalised polarisation when dhSM is present at a 
higher concentration in the membranes, suggesting an increase in membrane rigidity. Of note, 
this effect on membrane rigidity was observed by increasing dhSM only 30%, which is the 
same dhSM replacement measured by HPLC-MS in cells treated with GT11pyr at 30 µM for 
24h (Figure 25B). This is of particular interest to our work, since an increase in membrane 
rigidity could difficult the insertion of the fusion peptide in the target cell and additionally 
cholesterol in the membrane would be less accessible to recognition by the gp41 CRAC motif 
(Vincent et al., 2002). 
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Figure 30. Replacement of 
SM for dhSM increases the 
rigidity of liquid-ordered 
phases in giant unilamellar 
vesicles.
(A) Giant unilamellar vesi-
cles (GUVs) of PC:PE:SM:Ch 
(1:1:1:1) stained with Dil and 
NBD-Cer. (B) GUVs of PC:
PE:dhSM:Ch (1:1:1:1) stained 
with Dil and NBD-Cer.
The next step was to use more complex mixtures of lipids in giant unilamellar vesicles 
(GUVs), to better understand the effect of dhSM in more physiological conditions. GUVs of 
PC:PE:SM:Ch (1:1:1:1) or PC:PE:dhSM:Ch (1:1:1:1) composition were studied with confocal 
microscopy using two fluorescent probes, Dil and NBD-Cer. Dil is only able to incorporate 
itself in fluid phases, whereas NBD-Cer can insert itself in both fluid and liquid ordered phases, 
although it has difficulty incorporating itself in rigid structures; by analysing the different 
incorporation of each probe we can assess whether the substitution of SM by dhSM has an 
effect on phase formation in GUVs. As seen in Figure 30A, GUVs formed by PC:PE:SM:Ch 
present two distinct phases, one fluid (stained with Dil and NBD-Cer) and another liquid 
ordered (stained with only NBD-Cer). However, when SM is replaced by dhSM, NBD-Cer 
still stained the same regions as Dil (fluid phases), but there was less incorporation of NBD-
Cer in the remaining areas (corresponding to lo membranes) (Figure 30B). This suggests that 
the combination of dhSM with cholesterol has formed a more rigid phase than the previously 
SM-Ch liquid ordered regions in PC:PE:SM:Ch GUVs. This agrees with the results obtained 
with the Laurdan-labeled membranes presented above, and suggests that GT11 treatment may 
affect HIV-1 infection by increasing membrane rigidity, which in turn may impair the insertion 
of the gp41 fusion peptide in the host membrane.
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** Figure 31. HIV-1 pseudotyped viruses produced in GT11-treated cells are more infectious than viruses produced in control cells.
HIV-1 replication-deficient viruses pseudotyped with ADA enve-
lope were produced in HEK-293T cells incubated with 0 or 30 μM of 
GT11pyr for 36h, and used to infect TZM-b1 cells. Luciferase values, 
indicative of infection, were obtained for viruses produced in HEK-
293T cells (positive control) and are shown as 100% infection. The 
value obtained for viruses produced in the presence of GT11pyr was 
normalised in accordance. Bars indicate average + SD (n=3). Statisti-
cal differences are indicated (two-tailed T-student test), with regard 
to control viruses (produced in 293T cells): **, P<0.01.
2.8 Analysis of the infectivity of HIV-pseudotypes produced in GT11-incubated 
cells
 Lipid rafts not only are important in the entry of HIV-1 in the cell, but also in their exit 
from the infected cell, since the budding of newly-formed viral particles takes place in these 
microdomains in the membrane (Nguyen and Hildreth, 2000). To assess whether the modification 
of the lipid composition and membrane rigidity could alter the infectivity of newly-formed 
HIV-1 virions, ADA pseudotypes were produced in cells incubated with either 0 or 30 µM of 
GT11pyr (ADA-GT11 viruses). Furthermore, to ensure that GT11pyr present in the medium 
when recollecting the viruses does not affect the target cells when used in infection assays, the 
viral particles were ultracentrifuged and resuspended in fresh medium. Viral supernatants 
corresponding to 35 ng of p24 antigen were added to the TZM-b1 cells and the results from the 
infection are presented in Figure 31. We found that ADA-GT11 pseudotypes infected twice more 
effectively target cells than ADA viruses produced in non-treated cells. Unfortunately, no VSVG 
viruses were produced in the same conditions for comparison. Although a characterization of 
the SM/dhSM composition of the ADA-GT11 virions has not been performed, it is reasonable 
to envision that – as accounted for the recipient cells – their lipid composition would also be 
altered. Assuming this hypothesis, our results suggest that an enrichment of dhSM in the viral 
envelope would favour, rather than prevent, free virus-cell infection.
GT11 treatment inhibits both Env-mediated cell-cell fusion and infection by free HIV-
pseudotypes. Incubation of target cells with GT11 induces a replacement of SM for dhSM 
in lipid rafts, but does not affect T cell associated functions nor the localization of raft-
associated proteins. Higher dhSM content in membranes increases membrane rigidity. ADA 
pseudotypes produced in GT11-treated cells are more infectious than control viruses.
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The entry of HIV-1 in the target cell is a complex process that entails several coordinated 
interactions between viral and host elements. First, the viral gp120 glycoprotein needs to interact 
sequentially with the CD4 receptor and a chemokine coreceptor (Dalgleish et al., 184; Deng et 
al., 16; Feng et al., 16; Landau et al., 188; Thali et al., 13). Subsequently, the unfolding of 
the viral gp41 glycoprotein enables the insertion of the fusion peptides in the membrane of the 
cell, causing the formation of a fusion pore (Markosyan et al., 2003; Weissenhorn et al., 1). 
Although the process of entry essentially follows these well-defined steps, many other factors 
confer complexity to the process and are crucial for a successful infection (Dimitrov, 2000). 
Fusion between viral and host cell membranes is a cooperative process that requires the sum of 
many CD4-gp120-coreceptor complexes. In fact, it is estimated that four to six CCR5 receptors 
(Kuhmann et al., 2000), a number of CD4 molecules (Kuhmann et al., 2000; Layne et al., 10) 
and three to six Env trimmers are needed to form a fusion pore. In order for the formation of 
the entry complex, it is necessary the recruitment of the chemokine coreceptors in a CD4-gp120 
interaction dependent manner, which has been described in several studies (Lapham et al., 
16). The clustering required for HIV-1 infection is not a passive diffusion process, it depends 
on multiple intermolecular interactions on the cell surface modulated by rapid cytoskeleton 
reorganization (Gouin et al., 2005; Iyengar et al., 18; Jolly et al., 2004; Nguyen et al., 2005) and, 
at the plasma membrane, by the assembly of specialized lipid domains enriched in cholesterol, 
called lipid rafts (Hug et al., 2000; Liao et al., 2001; Manes et al., 2000; Popik et al., 2002; Viard et 
al., 2002). 
Lipid rafts are specific microdomains in the cell membrane mainly composed by 
sphingolipids, cholesterol and saturated phospholipids (Brown and London, 2000; Simons and 
Ikonen, 1). Due to their composition, these microdomains pack more tightly than the rest 
of the membrane, composed mostly by unsaturated phospholipids, and act as platforms that 
float in a fluid surrounding (Harder and Simons, 1). Importantly, several proteins segregate 
preferentially to lipid rafts, such as the receptors necessary for the entry of HIV-1 in the cell. 
Not only is the specific localization of these receptors in these domains essential for viral entry 
(Del Real et al., 2002), but also the clustering capacity of lipid rafts has to be intact for the 
formation of a trimeric gp120-CD4-coreceptor complex (Brown and Rose, 12; Manes et al., 
2000; Nguyen et al., 2005; Popik et al., 2002). The use of drugs that sequester cholesterol, such 
as methyl-ciclodextrins, has proven to disrupt lipid rafts and inhibit viral entry into the cell 
(Viard et al., 2002). Moreover, it has also been reported that the gp120 glycoprotein utilizes 
gangliosides present in lipid rafts as additional stabilizing factors for a successful entry to take 
place (Hammache et al., 1; Nehete et al., 2002). Indeed, in vitro studies have shown that it is 
possible to prevent HIV-1 entry in the target cell both by inhibiting sphingolipid synthesis and 
by blocking specific sphingolipids with neutralizing antibodies (Harouse et al., 11; Hug et al., 
2000; Puri et al., 2004). 
The entry of HIV-1 in the cell is not the only process in the infection cycle of the 
virus in which lipid rafts are important. In infected cells, several viral proteins are known to 
interact preferentially with raft microdomains in the cell membrane. The Gag and Gag-Pol 
precursors, for instance, possess myristoylation signals to ensure that these polyproteins are 
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directed to lipid rafts, the place where the assembly and release of new viral particles takes 
place (Lindwasser and Resh, 2001; Nguyen and Hildreth, 2000; Ono and Freed, 1; Wang et al., 
2000). In fact, studies have shown that the lipid composition of infectious HIV-1 virions is very 
similar to the one found in lipid rafts, and, additionally, cellular proteins that associate with 
lipid rafts have been detected in the envelope of HIV-1 viral particles (Aloia et al., 13; Arthur 
et al., 12).
In hope of further understanding the role and implication of lipid rafts in HIV-
1 infection, we devised two different strategies interfering with these microdomains. On 
one hand, we specifically targeted a peptide fusion inhibitor to lipid rafts and assayed this 
construct in fusion and infection experiments. On the other hand, we replaced sphingomyelin 
by dihydrosphingomyelin at the membrane of target cells, by use of a synthetic ceramide 
analogue, and analysed this effect in fusion and infection assays. 
effect of membrane-bound t20 in hiv-1 infection
 
 With the emergence of HIV-1 resistant strains to the antiretroviral drugs used in HAART 
(Martinez-Picado et al., 2000), there was a great need for the development of new drugs with 
different targets of inhibition. One attractive target was the entry of the virus in the cell, not 
only when the virus interacts with the cell receptors, but also when the gp41 subunits induce 
the fusion of the viral and cell membranes. For that purpose several C-peptides, derived from 
the HR2 region of gp41, were developed and tested in in vitro assays for inhibition potential 
(Chan and Kim, 18; Wild et al., 12; Wild et al., 14). The mechanism of action of these C-
peptides relies on the complementarity of their aminoacid residues to the HR1 region in gp41. 
Before the formation of the six-helix bundle, the gp41 subunits of the Env complex are found in 
a pre-fusion conformation with the HR1 regions exposed. At this stage, the C-peptides are able 
to recognize the complementary aminoacid residues in the HR1 region and attach to them, 
preventing the formation of the six-helix bundle and the consequent fusion of the membranes. 
Of the several C-peptides that showed promise in preventing HIV-1 entry in the cell, the T20 
peptide was the most efficient and the first to be approved for clinical use (Kilby et al., 18; 
Kliger et al., 2001; Wild et al., 14).
The T20 peptide inserts in the membrane of target cells
Recent reports have indicated that the T20 peptide has the propensity to insert itself in 
the outer leaflet of liposomes (Veiga et al., 2004), and for that reason it has been suggested that 
the cell membrane might act as a reservoir of T20 molecules for when the virus approaches 
the cell. By incubating culture cells with soluble T20 for 24h we were able to confirm the 
incorporation of the peptide in the membrane of live cells, in a dose-dependent manner. The 
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fact that, in vivo, the membrane of target cells might harbour T20 peptides that are readily 
available to inhibit the entry of HIV-1 in the cell, lead us to design a strategy that utilizes 
membrane-bound T20 to prevent viral entry in the cell. 
In 2001, Hildinger et al published a similar work using a T20-derived construct that 
is anchored to the membrane in an unspecific manner (Hildinger et al., 2001). They devised 
this strategy mainly as a response to the problems encountered with T20 administration in 
HIV-1 patients. In clinical use, T20 treatment is expensive and complicated, due to its lack of 
oral availability and the need for large amounts of the peptide to be delivered in order for an 
inhibitory effect to be produced. For these reasons the authors devised a strategy to express 
T20 in the membrane, as a gene therapy approach, in hope to surpass the drawbacks associated 
with T20 treatment. Our approach, however, differs from the one published by Hildinger et al 
in two main aspects: on one hand, we are anchoring T20 to the membrane specifically inside 
or outside lipid rafts, in hope to increase the local concentration of the peptide in sites of viral 
entry. On the other hand, by comparing the two different constructs, we expect to provide 
more evidence supporting the role of lipid rafts in HIV-1 infection. 
Overexpression of T20 at the membrane is ubiquitous
We constructed two different T20 versions, T20LDL and T20GPI. In the case of the 
T20LDL construct, the transmembrane region of the low-density lipoprotein receptor (LDLR) 
anchors the construct to the membrane but specifically in a region outside lipid rafts, whereas 
T20GPI possesses a glycosylphosphatidylinositol (GPI) anchor that attaches the construct 
to the outer leaflet of lipid rafts. By isolating the DRM faction in flotation experiments, we 
were able to detect a specific band in the DRM lane in the case of the T20GPI stable cell line, 
indicating that this construct is present in raft microdomains. Furthermore, we did not detect 
any band in the DRM lane in the case of T20LDL cells, suggesting that this construct does not 
partition in lipid rafts. Unfortunatelly, an unspecific band at the same molecular weight as 
the T20 constructs masked the location of T20LDL in the solubilised protein fraction of the 
gradients. Nonetheless, we can conclude from these analyses T20GPI is present in lipid rafts, 
whereas T20LDL is not. 
Concurring with this conclusion, we found that fluorescently-labeled antibodies induce 
clustering of the T20GPI peptide and the raft marker ganglioside GM1 by confocal microscopy. 
Unexpectedly, we found no difference in T20LDL or T20GPI colocalization with GM1; moreover, 
the levels of colocalization with GM1, i.e., presence in lipid rafts, are comparable to the ones 
found with a GFPGPI construct. 
It is possible and likely that the high expression of the constructs in the membrane 
is responsible for the loss of specificity in localization. We could not rule out, however, that 
both constructs behave similarly and are not exclusively located at the desired site in the 
membrane, i.e. T20GPI in lipid rafts and T20LDL outside lipid rafts. Although the results from 
the DRM isolation seemed to indicate that the constructs partitioned in the expected site in the 
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membrane, the immunofluorescence experiments did not confirm this result. 
Membrane-anchored T20 inhibits Env-mediated cell-cell fusion
Using the T20-expressing stable cell lines produced in HEK-293CD4 cells, we performed 
cell-cell fusion assays. The results indicate that both T20LDL and T20GPI inhibit Env-mediated 
cell-cell fusion equally well. Furthermore, this inhibition is comparable to the one achieved 
when the target cells are incubated with a low concentration of soluble T20 (between 0.5 and 
1 µg/mL). Given the unavailability of a method to quantify the levels of T20 expressed in the 
membrane of stable cell lines, we cannot properly compare the inhibitory efficiency of soluble 
and membrane-anchored T20 peptides. Nevertheless, our results demonstrate that both 
T20GPI and T20LDL inhibition potential. However, this assay failed to show the difference 
between anchoring T20 in lipid rafts or outside them; as expected, both constructs inhibited 
fusion at similar levels, since they are undistinguishable at the level of membrane expression 
and localization.
The efficiency of membrane-anchored gp41-derived peptides in inhibiting cell-cell 
fusion was also reported by Egelhoher et al, in 2004 (Egelhofer et al., 2004). In this case, the 
authors used a modified version of the construct first reported in (Hildinger et al., 2001), with 
improved expression and antiviral activity, and replaced the T20 peptide with another C-
peptide, C46. Their results confirmed that membrane-anchored C-peptides are efficient in 
inhibiting Env-mediated cell-cell fusion, as well as early steps of virus replication in single-
round infection assays. From this work followed a more recent development, in which primary 
rhesus monkey CD4+ lymphocytes expressing membrane-anchored C-peptides against simian 
immunodeficiency virus (SIV) are protected from SIV entry (Zahn et al., 2008). Furthermore, 
the expression of modified C-peptides against human or simian immunodeficiency viruses 
(HIV-1, SIV or SHIV) in stable cell lines prevents the entry of HIV-1, SIVmac251 and SHIV89.6P. 
These results help support the notion that the expression of gp41-derived C-peptides at the 
membrane of target cells is a feasible mechanism that does not alter the antiviral activity that 
these peptides show when in solution. 
Low expression of T20 in the membrane does not prevent infection 
by free HIV-1 viruses
In order to assess if membrane-anchored T20 is also able to block the entry of HIV-1 free 
viruses, we performed infection assays using replication-deficient HIV-1 pseudotypes. The 
target cells of infection were cells that express either T20LDL or T20GPI, but unfortunately we 
were not able to use the stable cell lines that express high levels of these constructs, since the 
infection levels were very low. To overcome this problem, we transiently transfected TZM-b1 
cells with either T20LDL or T20GPI and infected them with HIV-1 replication-deficient viruses 
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pseudotyped with an ADA (R5 HIV-1 strain) or a VSVG envelope. However, the results obtained 
from the infection assays were different than the ones expected after the fusion assays. The 
TZM-b1 cells that expressed T20 at the membrane were permissive for ADA entry, regardless 
of whether they expressed T20LDL or T20GPI. Surprisingly, the entry of VSVG pseudotypes 
was inhibited in T20-expressing cells, especially in the case of T20GPI, where the infection 
levels were no higher than 30% when compared with control TZM-b1 cells. The susceptibility 
of ADA viruses to inhibition by soluble T20 was confirmed when control TZM-b1 cells were 
incubated with several concentrations of this peptide, whereas VSVG viruses infected the cells 
in spite of T20 presence in the medium.
The explanation for the fact that membrane-anchored T20 does not prevent the entry 
of ADA pseudotypes might rely on the T20 expression levels of the target cells. It is possible 
that only 23% of expression is not sufficient to produce an antiviral effect and prevent infection 
by HIV-1 viruses. The fact that we were not able to use the same stable cell lines used in the 
fusion assays hinders any direct comparison between the two experiments. It was reasonable 
to assume that either T20 construct would protect cells from infection by free HIV-1 viruses, 
taking into consideration not only the results from the fusion assays, but also the published 
works of Hildinger et al and Egelhofer et al (Egelhofer et al., 2004; Hildinger et al., 2001). However, 
the conclusion that can be drawn from the infection experiments is that low levels of T20 at the 
membrane of target cells are insufficient to protect the cells from infection by HIV-1 viruses. 
HIV-1 pseudotypes produced in T20-expressing cells are more 
infectious than viruses produced in control cells
As was mentioned before, the assembly and release of new HIV-1 virions from the cell 
also takes place in lipid rafts (Nguyen and Hildreth, 2000). These microdomains serve as both 
portals of entry and exit from the cell, and the incorporation of cellular raft-associated proteins 
in the envelope of budding viruses is a common event (Arthur et al., 12). We decided to 
investigate the infectivity of HIV-1 pseudotypes produced in cells that express T20LDL or 
T20GPI in the membrane. Our starting hypothesis was that, when the viruses exited the 
producing cell, they would incorporate T20 in the viral envelope, which would temper with 
the ability of those viruses to approach and gain entry into a target cell. 
For this experiment we used not only the aforementioned ADA and VSVG envelopes, 
but also NL4.3 (X4 HIV-1 strain), and derivatives of these HIV-1 envelopes with reported 
mutations that confer resistance to T20-mediated inhibition: ADA 38E/42S, ADA 38A/42T 
and NL4.3 38E/42S. The first step was to test the infectivity of these viruses in cells treated 
with soluble T20 peptide. The results were surprising, because both wildtype NL4.3 and NL4.3 
38E/42S pseudotypes were resistant to T20-mediated inhibition. In contrast, the 38E/42S 
combination in the ADA envelope rendered the virus resistant to inhibition by soluble T20, 
although the highest concentration of the T20 peptide was able to inhibit viral entry by 40%. 
Indeed, the reported IC50 for enfuvirtide using NL4.3 pseudotypes with this double mutation 
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is around 6.2 µg/mL (Sista et al., 2004), which would explain why 10 µg/mL of soluble T20, in 
our experiment, is able to inhibit viral entry to some degree. A similar explanation can be given 
for the ADA 38A/42T double mutant, because this virus was as susceptible to T20-mediated 
inhibition as wildtype ADA. The reason behind this result is that the published IC50 associated 
with this double mutation is only around 1.7 µg/mL (Sista et al., 2004), lower than the lowest 
concentration of T20 assayed. Therefore, no resistance to T20 was detected with the 38A/42T 
aminoacid combination. As expected, the control VSVG envelope infected cells regardless of 
T20 concentration.
We then produced HIV-1 replication-deficient viruses pseudotyped with these envelopes 
in stable cell lines that express high levels of T20LDL or T20GPI. Since the NL4.3 wildtype 
envelope resistant to T20-mediated inhibition, NL4.3 38E/42S viruses were not produced. 
Intriguingly, the results showed that both wildtype and T20-resistant ADA viruses produced in 
T20-expressing cells (ADA-T20) were several orders of magnitude more infectious than ADA 
viruses produced in HEK-293T control cells. The same was not observed for NL4.3 viruses 
produced in T20-expressing cells (NL4.3-T20), which infected target cells at roughly the same 
level as viruses produced in control cells. Once again, VSVG viruses showed no difference in 
infectivity whether they were produced in T20-expressing cells or not.
Our hypothesis that T20 incorporated in the envelope would decrease the infectivity 
of newly-formed virions by interfering with the fusion mechanism appears therefore wrong. 
However, in 2006 Melikyan et al published a similar strategy in which they induced the 
expression of membrane-anchored C46 in effector cells and used them in cell-cell fusion assays 
(Melikyan et al., 2006). They proposed that, due to the orientation of the C-peptide, it would not 
be able to engage the gp41 glycoprotein present in the same cellular membrane and inhibit the 
formation of the six-helix bundle. Their hypothesis was only half correct, because although the 
antiviral potency of these membrane-anchored C-peptides was indeed significantly reduced 
when compared to the same peptides expressed in target cells, fusion was still inhibited by 
40%. 
Another possibility is that the incorporation of T20 in the envelope of newly-formed 
virions alters the fluidity of the membrane. Several studies have demonstrated that the 
increase in membrane fluidity in viral particles renders them more infectious, probably due 
to an enhancement in multiple-site binding. Likewise, a decrease in membrane fluidity is 
responsible for the loss in infectivity of viral particles (Harada, 2005; Harada et al., 2004; Harada 
et al., 2005). However, if this were the case, then T20 used in soluble form would increase 
infection by HIV-1 viruses, since it has a tendency to incorporate itself in the lipid bilayer and 
it would increase fluidity of the target cell membrane, which has also been reported to enhance 
infection (Owada et al., 18). The most likely explanation for the increased infectivity of HIV-1 
virions that carry T20 is that the membrane-anchored peptide is able to enhance and stabilize 
the attachment of the virus to the target cell, allowing for the establishment of the necessary 
interactions between the viral and cellular proteins. It has been reported that the incorporation 
of host-derived major histocompatibility complex (MHC) class II glycoproteins in nascent HIV-
1 viruses promotes infectivity by acting as additional adhesion molecules on the surface of the 
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target cell (Cantin et al., 1; Tremblay et al., 18). In our case, T20 would not be recognized by 
receptors present in the target cell, but it would allegedly insert itself in the outer leaflet of the 
cell membrane and anchor the virus to the site of entry. If this interpretation is correct, a major 
question is why the increased infectivity only happens for ADA-T20 but not for NL4.3-T20 
viruses. Although a western-blot analysis to confirm the presence of T20 in the viral envelope 
is missing, it is expected that ADA and NL4.3 virions would be generated following the same 
pathway. The molecular explanation behind the increased infectivity of ADA-T20 viruses but 
not of NL4.3-T20 viruses in our experimental setup requires further experiments.  
effect of the inhibition of dihydroceramide desaturase 
(dhcdase) in hiv-1 infection
 
 As was mentioned above, glycosphingolipids play an important part in HIV-1 entry 
in the cell. The implication of glycosphingolipids in the fusion process has been suggested by 
using PPMP, an inhibitor of the enzyme glycosyltransferase, which reduced the susceptibility 
of cells to infection and fusion by R5 and X4 HIV-1 viral strains (Hug et al., 2000; Puri et al., 
2004). Furthermore, it has been found that the gangliosides GM3 and Gb3 are able to interact 
with the viral glycoprotein gp120, suggesting their implication in the entry process, possibly as 
stabilizing cofactors of the Env-CD4-coreceptor ternary complex (Hammache et al., 1; Nehete 
et al., 2002). In addition, Harouse (Harouse et al., 11) showed that antiglycosphingolipid 
antibodies are able to prevent HIV-1 infection in vitro.
 These findings encouraged us to test the antiviral activity of a novel inhibitor of the 
ceramide biosynthetic pathway in HIV-1 infection. GT11 is a ceramide analogue that acts as a 
competitive inhibitor of the enzyme dihydroceramide desaturase (DHCDase). By inhibiting the 
enzyme, ceramide is not produced and its immediate precursor, dihydroceramide, predictably 
would accumulate in the cell. Consequently, saturated sphingolipids that lack a characteristic 
trans 4,5 double bond are synthesised, with different biophysical and structural properties 
than common unsaturated sphingolipids. GT11 was developed by Gemma Fabriàs laboratory 
at the IIQAB in Barcelona, and its inhibitory activity in vitro has been published (Triola et al., 
2004; Triola et al., 2001); in our experiments we used two different GT11 compounds, GT11 C8 
(with a fatty acid chain composed by 8 carbons) and hydrosoluble GT11pyr (a derivative of the 
original GT11 compound, with a pyrimidine ring).
We decided to study the implication of replacing unsaturated sphingolipids by 
saturated sphingolipids in vivo. Since lipid rafts are mainly composed by sphingolipids and 
cholesterol (Brown and London, 2000; Simons and Ikonen, 1), it is reasonable to assume that 
this drug will affect lipid raft composition and function; therefore, we tested the effect of GT11 
not only on basic raft-associated functions, but also on the ability to act as an antiviral agent 
against HIV-1.
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GT11 inhibits both Env-mediated cell-cell fusion and entry of free 
HIV-1 viruses in a dose-dependent manner
 As a proof-of-principle experiment, different concentrations of GT11 C8 were 
incubated with target cells in an Env-mediated cell-cell fusion assay. The results showed a 
dose-dependent decrease in the luciferase signal upon coculture of effector and target cells, 
indicative of the inhibition of cell-cell fusion caused by subtoxic doses of GT11 C8. Moreover, 
low concentrations of the compound were sufficient to induce an inhibitory effect (IC50 = 0.08 
µM), further straightening the evidence that GT11 C8 is functional and able to inhibit the entry 
of HIV-1 in the cell.
Following the results stated above, we decided to test GT11pyr in infection experiments 
with replication-deficient HIV-1 pseudotypes. Two approaches were followed: in one case, 
high concentrations of GT11pyr were incubated with target cells for a short period of time, 
whereas in the other case low concentrations of the compound were used over a longer period 
of time. In the first approach, target cells incubated with GT11pyr reported a strong inhibition 
in viral entry (at least 60%) for viruses pseudotyped with HIV-1 specific envelopes (ADA and 
NL4.3), when compared with VSVG viruses, whose infection rate was unaffected by GT11pyr. 
This effect, moreover, was detected for all concentrations tested (ranging 15 µM upwards), 
indicating that the compound was strongly antiviral under the test conditions. Regarding the 
second approach, the inhibitory effect was more subtle due to the experimental conditions, but 
when the target cells were treated with 0.5 µM of GT11pyr for 84h the entry of ADA viruses was 
specifically inhibited (around 50%) compared to VSVG viruses. Therefore, a longer incubation 
period is necessary to inhibit viral entry when lower concentrations of the compound are used. 
The most likely explanation is that the synthesis of saturated sphingolipids, in the presence of 
GT11pyr, is cumulative, and lower concentrations of the compound need more time to induce 
the same level of replacement of unsaturated sphingolipids for saturated sphingolipids as 
higher concentrations do. 
Subtoxic concentrations of GT11 do not affect T cell chemotaxis and 
activation
 After the fusion and infection experiments, we are able to conclude that both GT11 C8 
and GT11pyr possess antiviral activity against HIV-1 and are capable of inhibiting the entry 
of the virus in the cell. Presumably, this inhibitory effect derives from the change in lipid raft 
composition caused by the compounds. Given that lipid rafts are implicated in several cell 
processes (Fantini et al., 2002; Grassme et al., 2001; Inokuchi et al., 2000; Manes et al., 2003; Manes 
et al., 1), it is important to verify that GT11 does not impede T cell-associated functions, 
such as chemotaxis and activation. Upon stimulation, whether it be an antigen-presenting cell 
(APC) or a chemokine, raft clustering is essential for the reorganization of receptors in the 
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membrane and the formation of supramolecular clusters that transduce the stimulation signal 
into a cascade of events inside the cell (Manes and Viola, 2006; Viola and Gupta, 200). Since the 
use of other strategies that interfere with lipid rafts, namely cholesterol-sequestering drugs 
and sphingolipid depletion, have been known to impair certain cell functions (Hanada et al., 
15; Pike and Miller, 18), it is crucial to assess if GT11 incubation induces the same kind of 
effect in target cells.
The results indicate that GT11 C8 or GT11pyr, at subtoxic concentrations, did not inhibit 
CXCL12-mediated chemotaxis of peripheral blood mononuclear cells (PBMCs) or Jurkat cells. 
In fact, a slight increase of the migration index was detected when Jurkat cells were incubated 
with GT11 C8 at 2 µM; less pronounced increases were registered for Jurkat cells incubated with 
10 µM of GT11pyr, a concentration that affects cell growth, and PBMCs incubated with 2 and 5 
µM of GT11pyr. Furthermore, non-stimulated PBMCs incubated with several concentrations of 
GT11pyr were able to produce interferon-γ (IFNγ) upon CD3- and CD28-mediated activation, 
an indication that GT11pyr treatment does not impair T cell activation mechanisms.
GT11 alters the lipid composition of lipid rafts but does not affect the 
localization of raft-associated proteins
 Following the determination of GT11 antiviral activity in fusion and infection assays, 
and the confirmation that T cell-associated functions are intact, we next sought to verify if 
GT11 alters the lipid composition of lipid rafts by High Performance Liquid Chromatography 
coupled to time of fly mass spectrometry (HPLC-MS). The chromatograms showed that 
GT11pyr treatment induced a decrease in the amount of sphingomyelin (SM) in DRMs, 
associated with a corresponding increase in dihydrosphingomyelin (dhSM), the saturated 
version of sphingomyelin. Moreover, the dhSM/SM ratio was highest for 30 µM of GT11pyr, 
where a 30% replacement of SM for dhSM was detected. These results confirm that GT11pyr is 
able to inhibit DHCDase in vivo, and that such inhibition alters the lipid composition of lipid 
rafts.
 Just as the fractions from DRM isolation were analysed by HPLC-MS, a western-blot 
to determine the presence of raft-associated proteins was also performed. In this case, we 
were interested in determining the membrane partitioning of the CD4 receptor in GT11pyr-
incubated cells, since this receptor is used by HIV-1 to gain entry into the cell. The results from 
the western-blot showed us that CD4 partitioning to lipid rafts was unaltered when the cells 
were incubated with 30 µM of GT11pyr. This indicates that, although this concentration of 
GT11pyr is able to induce a substantial replacement of SM for dhSM in lipid rafts, the change in 
lipid composition does not affect the membrane localization of the CD4 receptor. In agreement 
with this idea, we found that GT11pyr did not change the colocalization of the CD4 receptor, 
the CXCR4 receptor or a GFPGPI construct with GM1, indicative of lipid rafts. An interesting 
observation is that the partition coefficient of CXCR4 in lipid rafts is lower than the one from 
the CD4 receptor, in non-stimulated conditions, as was reported before by Manes et al (Manes 
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et al., 2000).
Therefore, cell treatment with GT11pyr is able to alter the lipid composition of lipid rafts 
as theoretically proposed: sphingolipids no longer possess a ceramide backbone but instead 
a dihydroceramide one. This effect is expected because the inhibitor prevents the formation 
of ceramide in the cell, and the resulting sphingolipids mirror that inhibition. Strinkingly, this 
alteration is not sufficient to affect the localization of known raft-associated proteins, such 
as the CD4 receptor, the CXCR4 receptor and a GPI-anchored protein. This suggests that 
GT11pyr treatment is not as drastic as complete abolition of sphingolipid synthesis or the use 
of cholesterol-sequestering drugs, which are effective in preventing the entry of HIV-1 in the 
cell but also temper with other important cell functions (Hanada et al., 15; Hug et al., 2000; 
Manes et al., 2000; Pike and Miller, 18; Viard et al.). 
Replacement of sphingomyelin for dihydrosphingomyelin increases 
membrane rigidity
The replacement of SM for dhSM in lipid rafts appears not to disrupt the formation of 
these microdomains, but alters their biophysical properties. The formation of negative curvature 
structures are a requisite for the occurrence of membrane fusion between the virus and the target 
cell (Peisajovich et al., 2000). Using different mixtures of dielaidoylphosphatidylethanolamine 
(DEPE) with SM, dhSM and cholesterol (Ch), we were able to assess the effect of dhSM on the 
lamellar-inverted hexagonal phase transition. The results suggest that replacing SM for dhSM 
does not difficult the formation of negative curvature structures, since there was no change 
in the transition temperatures of DEPE-dhSM bilayers when compared to DEPE-SM bilayers. 
However, when analysing the generalised polarisation (Gp) of Laurdan-labeled membranes 
with different mixtures of SM, dhSM and Ch, we detected an increase in Gp when dhSM 
is present, consistent with an increase in membrane rigidity. Moreover, when labelling giant 
unilamellar vesicles (GUVs) of PC:PE:SM:Ch (1:1:1:1) or PC:PE:dhSM:Ch (1:1:1:1) composition 
with the fluorescent probes Dil and NBD-Cer, we discovered that dhSM presence interfered 
with the incorporation of NBD-Cer. This indicates that the combination of dhSM and Ch 
originated a more rigid phase than SM and Ch in PC:PE:SM:Ch GUVs.
From these experiments we can conclude that the change in lipid composition caused 
by GT11 treatment leads to lipid rafts with increased rigidity. The antiviral activity detected 
with GT11 compounds might be explained by this increase in rigidity, since the correct 
functioning of the gp41 fusion peptide might be affected (Vincent et al., 2002), but we also 
questioned whether this alteration influenced other aspects of the entry process. In particular, 
we wondered whether the mobility of the receptors for HIV-1 entry in the cell was affected by 
GT11-mediated increase in membrane rigidity, since clustering of receptors at the membrane 
of the cell is a necessary step for the formation of the trimeric gp120-CD4-coreceptor complex 
(Manes et al., 2000; Nguyen et al., 2005; Popik et al., 2002). For example, cholesterol depletion 
has been shown to decrease the mobility of EGF receptors (Orr et al., 2005) and even of CCR5, 
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although it did not alter CD4 mobility (Steffens and Hope, 2004). However, the effect of increased 
membrane rigidity on receptor mobility has been less studied.
As an attempt to measure the mobility of the CD4 receptor in the membrane, we 
devised a single-particle tracking (SPT) experiment with GT11-treated cells. This technique 
consists on the analysis of the trajectories of single-fluorescent dots on the membrane of 
live cells, with a specific software (MatLab), and uses Total Internal Reflection Fluorescence 
Microscopy (TIRFM) to obtain the data for analysis. As opposed to Epifluorescence, in which 
the total fluorescence of a given sample when excited in a specific wavelenght is captured, 
TIRFM selectively illuminates and excites fluorophores in a restricted region of the specimen 
immediately adjacent to the glass-water interface. Consequently, only a thin section of the 
sample (around 100 nm) is visualised and background fluorescence from outside the focal 
plane is elliminated. Preliminary results obtained in Maria Garcia-Parajo laboratory (IBEC, 
Barcelona) with untreated HEK293CD4 cells showed that the mean square displacement (MSD) 
values for the CD4 trajectories analysed (n=39) were best adjusted by a curve that corresponds 
to confined diffusion, with a diffusion coefficient (D) of 0.059 µm2/s. This indicates that the 
CD4 receptor, at the membrane of the tested control cells, exhibits a confined and not free 
diffusion, which might be indicative of the presence of the receptor in restricted environments. 
However, the analysis of the mobility of the CD4 receptor was not possible in GT11pyr-treated 
cells, due to slight alterations in the adhesivity of GT11pyr-treated cells which impeded the 
recording of image with enough quality for a confident analysis of the trajectories. We are 
currently studying alternative approaches to overcome these problems. 
HIV-1 pseudotypes produced in GT11-treated cells are more 
infectious than viruses produced in control cells
Previous studies have determined that the lipid composition of HIV-1 viral particles 
is an important factor in their infectivity (Aloia et al., 13). As such, our results with GT11 
instigated us to produce replication-deficient HIV-1 pseudotypes (ADA) in cells treated with 
GT11pyr and analyse their ability to infect target cells. The results showed that, contrary to 
expectations, ADA viruses produced in GT11-treated cells (ADA-GT11) were twice more 
infectious than viruses produced in control conditions. Although a lipid analysis of the viral 
envelope was not performed, it is reasonable to assume that the viral particles exited the cells 
through lipid rafts and retained the lipid composition of these microdomains in their envelope, 
as previously reported. Therefore, we can infer that an increase in membrane rigidity favours 
viral entry in the target cell.
The reason for improved infectivity of ADA-GT11 pseudotypes is not immediately 
clear. We have mentioned before that membrane fluidity is important for HIV-1 entry in the 
cell, but Harada et al (Harada et al., 2005) have published that decreased membrane fluidity of 
viruses hampers their ability to infect target cells, while an increase in fluidity favours it. In 
fact, in 2005 and 2007 the same authors reported on two different antiviral agents, glycyrrhizin 
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and fattiviracin FV-8, which act as fluidity modulators and inhibit infection by several viruses 
including HIV-1 (Harada, 2005; Harada et al., 200). They postulate that a decrease in membrane 
fluidity in cells treated with the compounds is responsible for inhibiting cell-cell fusion and 
infection by free viruses, similarly to GT11, although the mechanism of action was different: 
both glycyrrhizin and fattiviracin FV-8 are lipids that intercalate in the membrane of the cells 
and thus alter membrane fluidity. Furthermore, the authors refer that viruses treated with the 
compounds show a decrease in membrane fluidity that causes a reduction in viral infectivity, 
contrary to our results.
 These discrepant results are difficult to explain, and probably suggest that the anti-
retroviral effect of compounds that modify biophysical properties of the host and/or the 
viral membranes is complex and dependent of still unknown factors. Nonetheless, the results 
presented in this report are a very good starting point to think that these type of drugs can be 
added to the arsenal to fight against the HIV-1 pandemic.
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1. The T20 peptide inserts in the membrane of live cells, in a dose-dependent 
manner.
2. The expression of high levels of membrane-anchored T20 inhibits Env-mediated 
cell-cell fusion. Transient expression of the membrane-targeted T20 peptides 
are unable to block entry of HIV-1 pseudotyped viruses.
3. ADA HIV-1 pseudotypes produced in T20-expressing cells are more infectious 
than HIV-1 pseudotypes produced in control cells. This probably implicates 
T20 as an additional stabilizing anchor in virus-cell interactions.
4. Targeting dihydroceramide desaturase (DHCDase) activity with GT11 and 
GT11 derivative compounds inhibits Env-mediated cell-cell fusion in a dose-
dependent manner. Subtoxic doses of these compounds also specifically inhibit 
cell infection by HIV-1 pseudotyped viruses.
5. Inhibition of DHCDase activity in vivo produces a change in lipid rafts from 
unsaturated to saturated sphingolipids. The modification of lipid rafts at the lipid 
level does not result in an alteration of protein partitioning in detergent-resistant 
membranes, nor in an impairment of T cell chemotaxis and activation.
6. An increase in the dihydrosphingomyelin (dhSM) content of biological 
membranes enhances rigidity of liquid-ordered domains. This dhSM-induced 
increase in membrane rigidity may explain the ability of GT11 derivatives to 
inhibit HIV-1 entry.
. ADA HIV-pseudotypes produced in GT11-treated cells are more infectious than 
HIV-1 pseudotypes produced in control cells.
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INTRODUCCIÓN
 El virus de la inmunodeficiencia humana (VIH) es el agente causante de una de las 
pandemias que ha causado más muertes en todo el mundo, el Síndrome de la Inmunodeficiencia 
Adquirida (SIDA) (Barre-Sinoussi et al., 183; Hoffman, 200; Levy et al., 184). El VIH, un 
retrovirus perteneciente a la subfamilia Lentivirinae, tiene un genoma viral compuesto por 
dos moleculas de ARN dentro de una cápside ecosaédrica formada por proteínas virales. La 
capside está rodeada por una membrana lipídica derivada de la célula huésped, donde están 
anclados complejos de dos glicoproteínas virales (gp120 y gp41), importantes en el proceso de 
entrada del virus en la célula diana (Sierra et al., 2005; Turner and Summers, 1). Dos especies 
de VIH han sido identificadas, VIH-1 y VIH-2, siendo VIH-1 la especie más virulenta y la 
causante de la mayoría de las muertes asociadas a este síndrome (Reeves and Doms, 2002).
 El VIH-1 infecta esencialmente a linfocitos T y macrófagos (Dalgleish et al., 184; Landau 
et al., 188; Maddon et al., 186). El ciclo de infección del virus comienza con la entrada en 
la célula diana, un proceso que requiere la interacción secuencial de la glicoproteína de la 
envuelta viral gp120 con el receptor CD4 en la membrana de la célula diana, y posteriormente 
con un receptor de quimioquinas, usualmente CCR5 o CXCR4. La formación del complejo de 
entrada gp120-CD4-coreceptor concluye con la fusión de la membrana viral con la membrana 
de la célula, y la posterior liberación de la cápside viral en el citoplasma de la célula huésped 
(Chan and Kim, 18; Deng et al., 16; Feng et al., 16; Landau et al., 188; Markosyan et al., 
2003). Posteriormente el ARN viral es retrotranscripto en ADN de doble cadena, e insertado 
en el genoma celular. La transcripción y traducción del genoma viral en poliproteínas (Gag, 
Gag-Pol y Env) dará lugar a las proteínas esenciales para la formación de las nuevas partículas 
virales. Estas proteínas, junto con las dos copias del ARN viral se empaquetan y salen de la 
célula huésped a través de la membrana celular dando lugar a las nuevas partículas virales 
que, tras un proceso de maduración, estarán listas para iniciar un nuevo ciclo de infección 
(Bukrinskaya, 2004; Ganser-Pornillos et al., 2008; Gottlinger et al., 18; Jouvenet et al., 2006; 
Nguyen and Hildreth, 2000).
Varios fármacos han sido desarrollados a lo largo de los años con el objetivo de inhibir 
algún paso en el proceso de infección del VIH-1 (De Clercq, 2002). Con la aparición de cepas 
virales resistentes a los fármacos existentes, ha surgido la necesidad de ampliar la terapia 
utilizada contra esta enfermedad, y desarrollar nuevos compuestos con distintas dianas de 
acción (Hughes et al., 2008; Martinez-Picado et al., 2000). Uno de esos nuevos fármacos es el 
péptido T20, también llamado enfuvirtide, que es capaz de inhibir la fusión de las membranas 
viral y celular a concentraciones muy bajas y, como consecuencia, la entrada del virus en la 
célula (Kilby et al., 18; Wild et al., 14). T20 es un péptido con una secuencia de aminoácidos 
derivada de la región HR2 de la glicoproteína gp41, y complementaria a la región HR1 de la 
misma glicoproteína, lo que permite su interacción con dicha región en un estadio previo a 
la fusión de las membranas. El resultado es la inhibición la formación de un complejo de seis 
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hélices α necesario para que las membranas viral y celular se fusionen (Chan and Kim, 18; 
Wild et al., 12; Wild et al., 14). Este péptido ha surgido como una innovación en el campo 
de la lucha contra el SIDA, por ser el primer fármaco de la nueva clase antiviral de inhibidores 
de fusión.
Diversos estudios han demostrado que la infección por VIH-1 es un proceso dependiente 
de la integridad de unos dominios específicos de la membrana plasmática, denominados 
dominios de membrana tipo lipid rafts (Campbell et al., 2001). Los dominios de membrana lipid 
rafts son ensamblajes dinámicos de colesterol y esfingolípidos ricos en ácidos grasos saturados, 
que se localizan en la cara externa de la bicapa lipídica de la mayoría, si no de todas, las células 
eucariotas (Brown and London, 2000; Fridriksson et al., 1; Simons and Ikonen, 1). A pesar 
de su conformación ordenada, los rafts retienen una alta capacidad para difundir lateralmente 
en la membrana, aunque, a diferencia de los lípidos en dominios no-rafts que difunden como 
elementos individuales, los lípidos y proteínas incluidos en rafts difunden como un conjunto. Esta 
capacidad de movimiento permite, por un proceso de coalescencia, que proteínas inicialmente 
separadas en distintos rafts interaccionen entre sí (Harder and Simons, 1; Simons and Ikonen, 
1). Todas estas características hacen que estos dominios de membrana tengan un papel 
activo en la regulación de diversos procesos celulares que abarcan desde la transducción de 
señales  hasta la de entrada de patógenos intracelulares (Fantini et al., 2002; Grassme et al., 2001; 
Inokuchi et al., 2000; Manes et al., 2003; Manes et al., 1). Diferentes estudios han demostrado 
que estos dominios son usados por el virus para regular la interacción tanto espacial como 
temporal, entre gp120, CD4 y CXCR4 o CCR5  y para servir de plataforma de entrada del virus, 
aunque el mecanismo aún no se conoce en su totalidad (Del Real et al., 2002; Manes et al., 2000; 
Nguyen et al., 2005; Popik et al., 2002). Estos dominios también son usados por el VIH-1 como 
anclaje para la salida de los nuevos virus (Aloia et al., 13; Lindwasser and Resh, 2001; Nguyen 
and Hildreth, 2000; Ono and Freed, 1). 
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OBJECTIVOS
1. Expresar quimeras de T20 ancladas a la capa externa de membranas celulares 
y analizar sus efectos en infección por VIH-1.
1.1 Generar líneas estables que expresen T20 anclado a la membrana, específicamente 
asociado o excluido de lipid rafts.
1.2 Analizar el efecto de T20 anclado a la membrana en fusiones célula-célula mediadas 
por las proteínas de la envuelta del VIH-1.
1.3 Analizar el efecto de T20 anclado a la membrana en infección por virus pseudotipados 
con envueltas de VIH-1.
1.4 Determinar la infectividad de virus pseudotipados con envueltas de VIH-1 
producidos en células que expresan T20 en la membrana. 
2. Inhibir la enzima dihidroceramida desaturasa (DHCDasa) y analizar su efecto 
en infección por VIH-1.
2.1 Determinar la toxicidad celular del inhibidor de DHCDasa GT11, y su derivado 
GT11pyr.
2.2 Analizar el efecto de GT11 en fusión célula-célula mediada por las proteínas de la 
envuelta del VIH-1. 
2.3 Analizar el efecto de GT11 en infección por virus pseudotipados con envueltas del 
VIH-1. 
2.4 Estudiar el efecto de GT11 en funciones celulares asociadas a linfocitos T. 
2.5 Analizar la composición lipídica de lipid rafts en células tratadas con GT11.
2.6 Estudiar la localización de proteínas asociadas a lipid rafts en células tratadas con 
GT11. 
2. Estudiar las propiedades biofísicas de membranas que contienen 
dihidroesfingomielina.
2.8 Determinar la infectividad de virus pseudotipados con envueltas del VIH-1 
producidos en células tratadas con GT11.
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RESULTADOS
1. Efecto del anclaje de T20 a la membrana en la infección por VIH-1
T20 es un péptido soluble que inhibe la infección por VIH-1 al bloquear la fusión 
entre la membrana celular y la viral (Kilby et al., 18; Wild et al., 14). Estudios previos han 
demostrado que el péptido T20 posee la capacidad de insertarse en la capa externa de liposomas, 
y que esa característica puede estar relacionada con la actividad antiviral demostrada in vitro 
(Veiga et al., 2004). Nuestros resultados han confirmado la propensión del péptido a insertarse 
en la membrana plasmática de células vivas, evidencia que nos ha incitado a generar células 
que expresen de forma estable el péptido en la membrana para favorecer su efecto antiviral. 
Generamos dos construcciones de T20 anclado a la membrana: una quimera de T20 asociada 
a dominios de membrana tipo lipid rafts (T20GPI) y una quimera excluida de estos dominios 
(T20LDL). Nuestro objetivo es aumentar la concentración del péptido en el sitio de entrada 
del virus, y proporcionar así nuevos datos que apoyen la importancia de los lipid rafts en la 
infección por VIH-1. 
Inicialmente generamos líneas celulares estables que expresan altos niveles de 
T20LDL o T20GPI en la membrana. Comprobamos la localización de cada construcción en la 
membrana a través de gradientes de flotación en detergentes no iónicos y experimentos de 
inmunofluorescencia. Los resultados obtenidos de los gradientes de flotación indican que la 
construcción T20GPI está localizada en las fracciones correspondientes a membranas resistentes 
a la extracción por detergentes no iónicos, i. e. lipid rafts, mientras la construcción T20LDL no 
se encuentra en estos dominios. Desafortunadamente, la presencia de una banda inespecífica 
no ha permitido detectar T20LDL en la fracción correspondiente a proteínas solubilizadas. Los 
resultados de inmunofluorescencia, sin embargo, no han permitido confirmar este resultado ya 
que no se hallaron diferencias en la colocalización de cada construcción con el gangliósido GM1 
presente en los lipid rafts. Este resultado podría ser un efecto derivado de la sobreexpressión 
de T20 en la membrana, que origina una expresión ubicua de las construcciones y dificulta la 
distinción entre T20LDL y T20GPI.
Tras comprobar la expresión de ambas construcciones, el siguiente paso fue utilizar las 
líneas celulares estables para la expresión de T20 en ensayos de fusión célula-célula mediada 
por las proteínas de la envuelta del virus. Al poner en contacto células que expresan el complejo 
de la envuelta de VIH-1 en la membrana con células que sobreexpressan T20, se observó una 
reducción significativa en la fusión célula-célula tanto en el caso de T20LDL como en el caso 
de T20GPI. La eficiencia de T20 soluble para inhibir la fusión también ha sido comprobada. 
A diferencia del efecto de T20 que observamos en la fusión mediada por la envuelta viral, en 
ensayos de infección con virus deficientes en replicación pseudotipados con envueltas VIH-1 
o control (VSVG), observamos que la expresión baja de T20 en la membrana de la célula diana 
no es suficiente para inhibir la entrada de virus que utilizan CCR5 como coreceptor de entrada 
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(cepa ADA), aunque el péptido soluble es eficaz en prevenir la infección por VIH-1 de un 
modo dependiente de la dosis usada.
Por ultimo, analisamos la susceptibilidad a la inhibición por T20 de virus deficientes 
en replicación pseudotipados con diferentes envueltas provenientes de VIH-1 y de VSVG, 
y descubrimos que los virus que utilizan CXCR4 como coreceptor de entrada (cepa NL4.3) 
son resistentes al péptido, mientras que virus ADA son susceptibles. Además, virus ADA con 
mutaciones descritas que confieren resistencia a T20 (38E/42S y 38A/42T) son parcialmente 
susceptibles a la inhibición por T20 soluble. Todos estos pseudotipos fueron además producidos 
en células que sobreexpresan T20 en la membrana, y se observó que los virus ADA son mucho 
más infecciosos cuando provienen de células con T20 en la membrana, comparando con los 
mismos virus producidos en células control, y hasta con virus NL4.3, en los que la presencia 
de T20 apenas aumenta la infectividad. 
2. Efecto de la inhibición de dihidroceramida desaturasa (DHCDasa) en la 
infección por VIH-1
Existen muchas evidencias que apuntan a los esfingolípidos como factores esenciales 
para la entrada de VIH-1 en la célula, entre otras, se ha demostrado que la inhibición de la 
síntesis de esfingolípidos es capaz de prevenir la infección por VIH-1 (Hug et al., 2000; Puri 
et al., 2004). Por ese motivo hemos utilizado un compuesto, GT11, que inhibe la enzima 
dihidroceramida desaturasa (DHCDasa), responsable por la formación de ceramida a partir 
de dihidroceramida (Triola et al., 2004; Triola et al., 2001). Dos compuestos han sido usados 
en nuestros experimentos, por una parte GT11 C8, con una cadena larga de 8 carbonos, y 
GT11pyr, un derivado del GT11 original con una pirimidina.
Empezamos por analizar el efecto de ambos compuestos en la viabilidad de células T. 
Comprobamos que el tratamiento con GT11 C8 no afecta a la viabilidad de linfocitos aislados 
de sangre periférica (PBMCs), mientras que GT11pyr es tóxico en células Jurkat y PBMCs a 
concentraciones superiores a 5 µM. Para analizar la actividad antiviral de estos compuestos 
hicimos un ensayo de fusión célula-célula mediada por las proteínas de la envuelta viral 
utilizando células tratadas con distintas concentraciones de GT11 C8. Los resultados indican 
que GT11 C8 es capaz de inhibir la fusión célula-célula de un modo dependiente de la dosis, 
con una IC50 de 0.08 µM. Además, utilizando virus deficientes en replicación pseudotipados 
con envueltas VIH-1 comprobamos que GT11pyr es capaz de inhibir la infección de estos virus 
en células tratadas con el compuesto, de un modo dependiente de la dosis. Estos resultados 
indican que tanto GT11 C8 como GT11pyr son capaces de actuar como compuestos antivirales 
que previenen la infección por VIH-1.
Una vez establecida la eficacia de los compuestos para inhibir la entrada del virus 
en la célula, estudiamos el efecto de GT11 C8 y GT11pyr en funciones celulares asociadas a 
linfocitos T, como son la quimiotaxis y la activación a través del TCR. Los resultados indican 
que ninguno de los compuestos afecta negativamente a la quimiotaxis de células Jurkat y 
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PBMCs mediada por CXCL12, aunque observamos un incremento de la migración cuando 
tratamos las células con concentraciones altas. También detectamos que GT11pyr no afecta a 
la producción de IFNγ en PBMCs activados por CD3 y CD28. Asimismo, el tratamiento con 
GT11pyr no afecta a la localización de proteínas asociadas a lipid rafts, como son los receptores 
CD4 y CXCR4 y la proteína GFPGPI, a pesar de que el análisis de las fracciones de membrana 
resistentes a la extracción por detergentes no iónicos por HPLC-MS ha demostrado que hay un 
reemplazamiento de esfingomielina por dihidroesfingomielina cuando las células son tratadas 
con GT11pyr. Hemos demostrado que dicho reemplazamiento es capaz de aumentar la rigidez 
de la membrana, pudiendo explicar el efecto antiviral de los compuestos.
Por ultimo, observamos que virus deficientes en replicación pseudotipados con una 
envuelta ADA producidos en células tratadas con GT11pyr tenían una mayor infectividad que 
los mismos virus producidos en células control.
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DISCUSIÓN
La entrada de VIH-1 en la célula diana es un proceso complejo que implica la interacción 
de la glicoproteína viral gp120 con los receptores celulares CD4 y CCR5/CXCR4, la formación 
del complejo trimérico gp120-CD4-coreceptor y finalmente la fusión de la membrana celular y 
viral mediada por la glicoproteína gp41 (Chan and Kim, 18; Deng et al., 16; Feng et al., 16; 
Landau et al., 188; Markosyan et al., 2003). La correcta formación del complejo de entrada del 
virus es dependiente tanto de la localización de estos receptores en dominios de membrana 
tipo raft, como de la capacidad de coalescencia de estos dominios (Del Real et al., 2002; Manes 
et al., 2000; Nguyen et al., 2005; Popik et al., 2002). No solo la entrada del virus en la célula es 
dependiente de lipid rafts, también la salida de los virus ocurre a través de estas regiones de 
membrana, con la incorporación de proteínas celulares asociadas a rafts en la envuelta de las 
nuevas partículas virales (Aloia et al., 13; Arthur et al., 12; Cantin et al., 1; Lindwasser and 
Resh, 2001; Nguyen and Hildreth, 2000; Ono and Freed, 1).
Con el objetivo de interferir de forma específica en la entrada del VIH-1 y determinar la 
importancia de la composición lipídica de la membrana de la célula diana para dicho proceso, 
llevamos a cabo dos abordajes, con la evidencia de que el virus utiliza los dominios de membrana 
tipos rafts como puerta de entrada. En primer lugar generamos péptidos con capacidad antiviral 
(T20) anclados de forma estable a la membrana de la célula diana, dirigiéndolos a dominios 
específicos de la misma. En un segundo abordaje alteramos químicamente la composición 
lipídica de la membrana celular, reemplazando esfingomielina por dihidroesfingomielina, y 
estudiamos su efecto en la infección por VIH-1. 
El análisis de T20 comenzó confirmando que el péptido T20 es capaz de insertarse en 
la membrana de células vivas, como había sido descrito por otros autores en experimentos con 
liposomas (Veiga et al., 2004). Posteriormente, estudiando su efecto en la entrada del VIH-1, 
observamos que la expresión de T20 expresado en la membrana de células diana es capaz de 
prevenir la fusión célula-célula mediada por las proteína de la envuelta del virus. Sin embargo, 
no detectamos diferencias entre una versión de T20 anclada a los lipid rafts de otra excluida 
de estos dominios, posiblemente porque la sobreexpressión de estas construcciones las hace 
ubicuas en la membrana. Asimismo, podemos concluir que la baja expresión de T20 en la 
membrana no es suficiente para inhibir la entrada de virus ADA en las células, a pesar de que 
T20 en solución sí es efectivo en inhibir la infección por VIH-1. Este abordaje experimental es 
similar al trabajo publicado por Hildinger et al y Egelhofer et al (Egelhofer et al., 2004; Hildinger 
et al., 2001), en el cual los autores diseñan versiones de T20 y otros péptidos derivados de gp41 
anclados a la membrana de células diana, determinando que estos péptidos poseen actividad 
antiviral no solo frente a VIH-1 sino también frente a SIV y SHIV. Nuestra estrategia va más 
allá, al diferenciar entre una versión de T20 asociada a lipid rafts, puerta de entrada del virus, 
o excluida de estos dominios. Asimismo comprobamos que la expresión en la membrana de 
péptidos derivados de gp41 no afecta a la capacidad antiviral que estos péptidos demuestran 
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en solución. Sin embargo, observamos que virus producidos en células que expresan T20 en 
la membrana plasmática son más infectivos. Este resultado contradice el trabajo publicado 
por Melikyan et al (Melikyan et al., 2006), donde se describe que T20 presente en la envuelta 
de los virus es capaz de inhibir la entrada en la célula diana. Es posible que, al igual que otras 
proteínas celulares existentes en la envuelta del virus que actúan como factores de anclaje del 
virus a la célula diana (Cantin et al., 1; Tremblay et al., 18), T20 pueda insertarse en la 
membrana de la célula diana y ayudar a estabilizar la interacción virus-célula.
En el segundo abordaje, determinamos que GT11 C8, un compuesto inhibidor de la 
enzima dihidroceramida desaturasa (DHCDasa) (Triola et al., 2004; Triola et al., 2001), previene 
la fusión célula-célula mediada por las proteínas de la envueltas de VIH-1 de un modo 
dependiente de la dosis. Confirmando este resultado, GT11pyr, un derivado hidrosoluble de 
GT11 C8, es capaz de inhibir la entrada de virus ADA y NL4.3 de un modo dependiente de 
la dosis. Estos resultados indican que ambos compuestos, a concentraciones subtóxicas, son 
efectivos como agentes antivirales. El tratamiento de células T con GT11 C8 y GT11pyr no 
afectan ni a su capacidad quimiotáctica mediada por CXCL12 ni a su activación vía TCR. 
Tampoco observamos ninguna alteración en la localización de proteínas asociadas a lipid rafts, 
incluyendo los receptores utilizados por VIH-1 para entrar en la célula. Sin embargo, estudios 
de HPLC-MS han demostrado que GT11pyr induce un reemplazamiento de esfingomielina por 
dihidroesfingomielina en los dominios de membrana tipo raft que, en consecuencia, conduce a 
un aumento en la rigidez de membrana. Estos datos pueden explicar la actividad antiviral de 
GT11, ya que un aumento en la rigidez de membrana afecta negativamente a la interacción de 
la glicoproteína gp41 con la célula, impidiendo la entrada del virus. Por ultimo, observamos 
que virus producidos en células tratadas con GT11pyr tienen aumentada su capacidad 
infectiva, resultado que contradice el trabajo publicado por Harada et al con otros compuestos 
(Harada, 2005; Harada et al., 200). En dicho trabajo, y en otros (Harada et al., 2005), los autores 
describen que la disminución de la fluidez de la membrana viral inhibe la infección, mientras 
que un aumento la favorece. Nuestros datos indican que el efecto antiviral de drogas que 
modifican las propiedades biofísicas de las membranas, ya sea del virus o de la célula huésped, 
es complejo y dependiente de factores desconocidos. Sin embargo, los resultados mostrados en 
esta memoria nos incitan a pensar en compuestos moduladores de la fluidez de membranas 
como posibles fármacos a usar contra VIH-1.
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CONCLUSIONES
1. El péptido T20 se inserta en la membrana de células vivas de un modo 
dependiente de la dosis.
2. La expresión de altos niveles de T20 anclado a la membrana inhibe la fusión 
célula-célula mediada por las proteínas de la envuelta del VIH-1. La expresión 
transitoria de T20 anclado a la membrana no bloquea la entrada del VIH-1.
3. Virus VIH-1 pseudotipados con la envuelta ADA producidos en células que 
expresan T20 en la membrana son más infecciosos que estos mismos virus 
producidos en células control. Este efecto podría deberse a que T20 actúa como 
estabilizador en la unión virus-célula.
4.  La inhibición de la enzima dihidroceramida desaturasa (DHCDasa) por GT11 
y compuestos derivados del mismo, bloquea la fusión célula-célula mediada 
por las proteínas de la envuelta del VIH-1 de un modo dependiente de la dosis. 
Concentraciones subtóxicas de estos compuestos inhiben la infección por VIH-
1.
5. La inhibición de la enzima dihidroceramida desaturasa (DHCDasa) in vivo 
produce un reemplazamiento de esfingolípidos insaturados a saturados en 
los lipid rafts. Dicho reemplazamiento no afecta a la localización de proteínas 
asociadas a lipid rafts, ni a funciones esenciales de células T, como son la 
quimiotaxis y la activación vía TCR.
6. El incremento de dihidroesfingomielina en membranas biológicas aumenta 
la rigidez de la fase de membrana líquido-ordenada. Este aumento de rigidez 
podría explicar la capacidad de los derivados de GT11 para inhibir la entrada 
del VIH-1 en la célula.
. Virus VIH-1 pseudotipados con la envuelta ADA producidos en células tratadas 
con GT11 son más infecciosos que los mismos virus producidos en células 
control. 
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